Index to Volume 4

Author Index

Acar, J. F., 270, 351
Addison, W. A., S701
Akpom, C. A., 776
Albritton, W. L., S848
Al-Shammari, A. J. N., S109
Altmann, G., 351
Alvarez, S., 390
Angehrn, P., 372
Arnold, K., 551
Austrian, R., 1071 (erratum)
Baer, H., 378, 388
Banai, M., S185
Bang, N. U., S546
Bannister, E. R., 13
Bantock, H. M., 461
Banwell, J. G., 830
Barile, M. F., S1
Barry, A. L., S316, S366
Barsanti, R. G., 514
Bartlett, J. G., S664
Barza, M., S670
Baseman, J. B., S200
Bawdon, R. E., 1075
Beisel, W. R., 746
Benard, J., S392
Bergogne-Berezin, E., S392
Bermudez, R. H., 638
Bernstein, L. S., 411
Biddle, J. W., S848
Bilharz, T., 727
Black, R. E., 540
Blackburn, B. O., 351
Blackmore, C. A., S877
Blaser, J., S581
Blaser, M. J., 1196
Bloch, K., S93
Bodey, G. P., 78, 579
Böhni, E., 372
Bonetti, A., S581
Bongaerts, G. P. A., S527
Bové, J. M., S129, S141, S154
Bowers, J. T., S639
Bowman, B. B., 763
Braine, H. G., 586
Brown, S. T., S837
Brumfitt, W., 402
Brunham, R. C., 491
Budrich, P., 665
Buening, M. K., S555
Bunnell, W. W., 1026
Burchall, J. J., 246
Burkey, L. G., S683
Burrell, C. J., 619
Bushby, M. B., 315, 326
Busuttil, R. W., S650, S676
Butler, T., 551
Cabada, F. J., 533
Calaway, E. L., S597
Calloway, D. H., 736, 891
Carney, D. N., 1
Carroll, V. J., S163
Carson, J. L., S173
Cassell, G. H., S18
Cates, W., S877
Chaffey, J., 638
Chandra, R. K., 756
Chao, L., 351
Cheigh, J. S., 1208
Cherubin, C. E., S406, 734
Cheung, H. C., S210
Chew, W. H., 1107
Chodosh, S., 517
Christiansson, A., S43
Cisneros, L., 540
Clements, M. L., 540
Cobbs, C. G., 665
Cohen, M. L., S864
Cohen, M. S., 992
Cole, R. M., S115, S120,
Collier, A. M., S173
Collins, C. D., S683
Conklin, R. H., 315
Coombes, J. D., S325
Corey, G. R., 311
Corrado, M. L., S406
Cosimi, A. B., 614
Counts, G. W., 450, 484
Courtieu, A.-L., 351
Crane, L. R., 1075
Crowley, M., 449
Crumpacker, C. S., III, 1069
Cunningham, F. G., S696
Curtin, J., 97
Dabernat, H. J., S401
Dahl, C. E., S93
Dahl, J. S., S93
Daikos, G. K., S629
Daniel, T. M., 1254
Daniels, M. J., S167
Davis, B. D., 237
Davis, R. E., S122
Daya, V., 540
DeGorce-Dumas, J. R., S129
Delacrétaz, F., 1071
Del Bene, V. E., S683
Delmas, C., S401
DeMaria, A., Jr., 390
Dezfulian, M., S664
Dhawan, V. K., 1133
Diamond, L. S., 843
Dickson, J., 619
Dismukes, W. E., 665
Doerr, B. I., S354
Doluisio, J. F., S333
Duma, R. J., 1107
Dournovo, P., S392
Dretler, R. H., S747
Drotman, D. P., S788
Drusano, G. L., S585
Dubois-Dalcq, M., 999
Duff, D., 467
DuPont, H. L., 533
DuPont, M. W., 533
Durack, D. T., 311
Echols, R. M., 656
Edelson, P. J., 124
Edward, D. G. ff., S229
Efrati, H., S85
Eichel, B., 517
Eliopoulos, G. M., 282
Elliott, A., 665
Ellis, C., 517
Ellner, J. J., 698
Elwell, L. P., 246
Ericson, J. F., 566
Ernst, J. D., 302
Evans, A. S., 1068
Evans, D. A., 351
Evans, D. G., 533
Evans, D. J., Jr., 533
Fabricus, K., S688
Fainstein, V., 78
Fang, L. S. T., 444
Farquhar, J. A., 419
Feldner, J., S185
Feigin, R. D., S597
Fenner, F., 916
Fernald, G. W., S201
Fillastre, J.-P., S379
Finland, M., 185
Fisher, J. F., 1107
Fling, M. E., 246
Flournoy, N., 1119
Fossieck, B. E., Jr., 1
Freundt, E. A., S3
Friesen, H. A., 86
Fuchs, P. C., S316
Fujii, R., S656
Gabridge, M. G., S179
Gall, S. A., S701
Ganem, D., 1026
Gerster, J. C., 1071
Giamarellou, H., S629
Gibbs, R. S., S696
Gilchrist, M. J. R., S511
Gilman, R. H., 824
Gilmore, C., 78
Glauser, M. P., 1071
Gleckman, R., 449

Index to Volume 4

Author Index

Acar, J. F., 270, 351
Addison, W. A., S701
Akpom, C. A., 776
Albritton, W. L., S848
Al-Shammari, A. J. N., S109
Altmann, G., 351
Alvarez, S., 390
Angehrn, P., 372
Arnold, K., 551
Austrian, R., 1071 (erratum)
Baer, H., 378, 388
Banai, M., S185
Bang, N. U., S546
Bannister, E. R., 13
Bantock, H. M., 461
Banwell, J. G., 830
Barile, M. F., S1
Barry, A. L., S316, S366
Barsanti, R. G., 514
Bartlett, J. G., S664
Barza, M., S670
Baseman, J. B., S200
Bawdon, R. E., 1075
Beisel, W. R., 746
Benard, J., S392
Bergogne-Berezin, E., S392
Bermudez, R. H., 638
Bernstein, L. S., 411
Biddle, J. W., S848
Bilharz, T., 727
Black, R. E., 540
Blackburn, B. O., 351
Blackmore, C. A., S877
Blaser, J., S581
Blaser, M. J., 1196
Bloch, K., S93
Bodey, G. P., 78, 579
Böhni, E., 372
Bonetti, A., S581
Bongaerts, G. P. A., S527
Bové, J. M., S129, S141, S154
Bowers, J. T., S639
Bowman, B. B., 763
Braine, H. G., 586
Brown, S. T., S837
Brumfitt, W., 402
Brunham, R. C., 491
Budrich, P., 665
Buening, M. K., S555
Bunnell, W. W., 1026
Burchall, J. J., 246
Burkey, L. G., S683
Burrell, C. J., 619
Bushby, M. B., 315, 326
Busuttil, R. W., S650, S676
Butler, T., 551
Cabada, F. J., 533
Calaway, E. L., S597
Calloway, D. H., 736, 891
Carney, D. N., 1
Carroll, V. J., S163
Carson, J. L., S173
Cassell, G. H., S18
Cates, W., S877
Chaffey, J., 638
Chandra, R. K., 756
Chao, L., 351
Cheigh, J. S., 1208
Cherubin, C. E., S406, 734
Cheung, H. C., S210
Chew, W. H., 1107
Chodosh, S., 517
Christiansson, A., S43
Cisneros, L., 540
Clements, M. L., 540
Cobbs, C. G., 665
Cohen, M. L., S864
Cohen, M. S., 992
Cole, R. M., S115, S120,
Collier, A. M., S173
Collins, C. D., S683
Conklin, R. H., 315
Coombes, J. D., S325
Corey, G. R., 311
Corrado, M. L., S406
Cosimi, A. B., 614
Counts, G. W., 450, 484
Courtieu, A.-L., 351
Crane, L. R., 1075
Crowley, M., 449
Crumpacker, C. S., III, 1069
Cunningham, F. G., S696
Curtin, J., 97
Dabernat, H. J., S401
Dahl, C. E., S93
Dahl, J. S., S93
Daikos, G. K., S629
Daniel, T. M., 1254
Daniels, M. J., S167
Davis, B. D., 237
Davis, R. E., S122
Daya, V., 540
DeGorce-Dumas, J. R., S129
Delacrétaz, F., 1071
Del Bene, V. E., S683
Delmas, C., S401
DeMaria, A., Jr., 390
Dezfulian, M., S664
Dhawan, V. K., 1133
Diamond, L. S., 843
Dickson, J., 619
Dismukes, W. E., 665
Doerr, B. I., S354
Doluisio, J. F., S333
Duma, R. J., 1107
Dournovo, P., S392
Dretler, R. H., S747
Drotman, D. P., S788
Drusano, G. L., S585
Dubois-Dalcq, M., 999
Duff, D., 467
DuPont, H. L., 533
DuPont, M. W., 533
Durack, D. T., 311
Echols, R. M., 656
Edelson, P. J., 124
Edward, D. G. ff., S229
Efrati, H., S85
Eichel, B., 517
Eliopoulos, G. M., 282
Elliott, A., 665
Ellis, C., 517
Ellner, J. J., 698
Elwell, L. P., 246
Ericson, J. F., 566
Ernst, J. D., 302
Evans, A. S., 1068
Evans, D. A., 351
Evans, D. G., 533
Evans, D. J., Jr., 533
Fabricus, K., S688
Fainstein, V., 78
Fang, L. S. T., 444
Farquhar, J. A., 419
Feldner, J., S185
Feigin, R. D., S597
Fenner, F., 916
Fernald, G. W., S201
Fillastre, J.-P., S379
Finland, M., 185
Fisher, J. F., 1107
Fling, M. E., 246
Flournoy, N., 1119
Fossieck, B. E., Jr., 1
Freundt, E. A., S3
Friesen, H. A., 86
Fuchs, P. C., S316
Fujii, R., S656
Gabridge, M. G., S179
Gall, S. A., S701
Ganem, D., 1026
Gerster, J. C., 1071
Giamarellou, H., S629
Gibbs, R. S., S696
Gilchrist, M. J. R., S511
Gilman, R. H., 824
Gilmore, C., 78
Glauser, M. P., 1071
Gleckman, R., 449

Glomot, R., S354
Godin, M., S379
Goldberger, A. C., 1220
Goldstein, E. J. C., S406
Goldstein, F. W., 270
Goodrich, J. T., S778
Gorham, C. C., 566
Goto, S., S501
Gray, G. J., 438
Greaves, W. L., S857
Greenberg, N., S99
Griffiss, J. M., 159
Grose, W. E., 579
Grüneberg, R. N., 461
Guerrant, R. L., 1185
Guinan, M. E., S819
Gurwith, M., 593
Gutiérrez, J. J., 638
Guzman, M., 351
Haberer, K., S105
Hamilton-Miller, J. M. T., 402
Hammerschlag, M. R., 500
Harding, G. K. M., 438
Harada, Y., S536
Harmon, J., 665
Harrington, P. T., 638
Harvey, R. J., 255
Hasegawa, Y., S536
Haspel, M. V., 999
Heidenreich, R. O., S546
Hemsell, D. L., S696
Hill, G. B., S701
Hinman, A. R., 933
Hinthorn, D., 593
Holland, N. H., 467
Hollowell, D. C., 315, 326
Holmes, K. K., 450, 484, 491
Holmes, K., 999
Holmes, M., 351
Hooghe-Peters, E., 999
Hopfer, R. L., 78
Horwitz, M. A., 104
House, W. C., 1107
Huang, A. S., 998
Hughes, D. T. D., 528
Hughes, W. T., 602
Humbert, G., S379
Hutchinson, D. B. A., 419
Ings, R. M. J., S379
Iravani, A., 378, 388
Jackson, G. G., S720
Jacobs, M. R., 351
Jaffe, H. W., S842
Jägersten, C. I. C., S73
Jason, J., S883
Jick, H., 426
Johansson, K.-E., S73
Johansson, L. B.-A., S43
John, J. F., Jr., 13
Joiner, K. A., S664
Jones, R. N., S300, S316, S366
Junca, P., S129
Juranek, D. D., S857
Kabins, S. A., S842
Kahane, I., S185
Kammer, R. B., S712
Kapila, R., 332
Kaplan, S. L., S597
Kasanen, A., 358
Kass, E. H., 185, 434
Katz, M., 768, 805
Kaufman, H. W., S842
Kazee, M., 467
Keating, M. J., 579
Kelly, M., 444
Kent, R. L., 351
Keusch, G. T., 735, 751, 880, 901
Khan, A., S43
Khan, W. N., 514
Kief, H., S354
Klastersky, J., 294
Klein, J. O., 390
Knobler, R. L., 999
Kobayashi, F., S536
Koornhof, H. J., 351
Kramer, D. G., S883
Kramer, M., S354
Kraus, S. J., S848
Kreuger, E., S688
Kulkarni, R., 390
Kumazawa, J., S692
Kuo, C., 491
Kurtz, T. O., S650
Kusmiesz, H., 546
Kutner, S., S85
Kvernland, S. J., S597
Labia, R., S529
Latham, M. C., 822, 896
Laveran, C. L. A., 908
Lawson, D. H., 429
Leblanc, G., S59
Lee, I. M., S122
Le Grimellec, C., S59
Leroy, A., S379
Levine, M. M., 540
Levy, C., 97
Lietman, P. S., 586
Lindblom, G., S43
Lipsky, B. A., 1220
Liss, A., S115,
Liu, C., 593
Long, G. W., 656
Lossick, J. G., S801, S819
Louria, D. B., 332
Lüthy, R., S581
Lyons, R. W., 733
Madsen, P. O., S416
Mahmoud, A. A. F., 698
Maksymiuk, A., 78
Mandell, G. A., S639
Mandell, L., 638
Maniloff, J., S105
Mann, R., 514
Marchant, C., 506
Margolis, S.,
Marien, G. J. R., S664
Marks, C. A., S546
Marmion, B. P., 619
Marsden, P. D., 885
Masur, H., 1208
Mason, E. O., S597
Mata, L., 870, 871
Mattler, L. E., S546
Mayhall, C. G., 1107
McCabe, W. R., 390
McCoy, R. E., S157, S171
McCracken, G. H., Jr., S595, S603
McElhaney, R. N., S50
McGrattan, M. A., S676
McGregor, I. A., 798
McKevitt, M., 450, 484
McNamee, W. B., S585
McRoberts, J. W., 467
Meares, E. M., Jr., 475
Medeiros, A. A., 351
Medici, T. C., 517
Melchior, D. L., S35
Menara, A., S141
Meyers, B. R., S411
Meyers, J. D., 1119
Migasena, P., 880
Minion, F. C., S210
Minna, J. D., 1
Moellering, R. C., Jr., 282, S489, S708
Monrocq, N., S392
Morel, C., S392
Morton, D. M., S536
Mouches, C., S141
Mouton, R. P., S527
Mueller, O., S688
Muraoka, Y., S536
Murphy, T. F., S670
Naot, Y., S205
Nathanson, N., 940
Natsios, G. A., 449
Nelson, J. D., 546
Neu, H. C., S288, 366, 374
Newman, L. S., 1096
Nhami, A., S129
Nicolle, L. E., 438
Nolan, C. M., S396
Norden, C. W., 276
Normand, I. C. S., 461
Norton, R. A., 351
Novick, W. J., Jr., S346
Oblinger, M. J., S639
O'Brien, T. F., 351
Op den Kamp, J. A. F., S71, S80
Owen, R. L., S864
Paice, B. J., 429

Palchaudhuri, S., 1075
Palmer, D. L., 656
Parker, R. H., 1
Pasculle, A. W., 351
Paul, J. R., 1062
Pawlowski, Z. S., 806
Perfect, J. R., 311
Perkins, R. L., S421
Perlino, C. A., S617
Pichichero, M. E., 86
Pierre, J., S392
Pines, J. M., 883
Platt, R., 185
Plorde, J. J., 1220
Plozza-Nottebrock, H., 372
Polk, B. F., 29
Pollock, A. A., 562
Preston, D. A., S516
Quiñones-Soto, R., 638
Rahal, J. J., Jr., 562, S606
Rahman, K. M. M., 985
Rambo, W. M., S683
Ramírez-Ronda, C. H., 638
Ravdin, J. I., 1185
Razin, S., S1, S85, S185
Reddy, V., 820
Rentier, B., 999
Reynaert, P., 173
Ricard, B., S129
Richard, G. A., 378, 388
Richmond, D. K., S683
Richmond, M. H., S516
Rilfors, L., S43
Rios, N., 533
Robinson, H. L., 1015
Rocha, H., 783
Rodríguez, W. J., 514
Rodwell, A. W., S8
Ronald, A. R., 438
Rosenberg, I. H., 763
Ross, S., 514
Rottem, S., S35, S85, S97, S99
Rubin, R. H., 444, 614
Rueckert, U., S688
Rumans, L., 551
Running, K., 484
Russell, N. J., 528
Russell, P. S., 614
Ryan, P. A., S585
Saillard, C., S129
Saito, A., S623
Sakaguchi, T., S354
Salter, A. J., 196, 338
Sande, M. A., 302, S639
Saral, R., 586
Satterwhite, T. K.,
Schaad, U. B., S603
Schassan, H.-H., S610
Schiefer, H.-G., S65
Schmidt, U., 332
Shimada, J., S569
Schimpff, S. C., S585
Schultz, M. G., 815, S864
Schummer, U., S65
Schwartz, R. H., 514
Sen, P., 332
Septimus, E. J., 315
Sepúlveda, B., 836, 1247
Sever, J. L., 136
Shadomy, S., 1107
Shamsuddin, D., 97
Sharbaugh, R. J., 13
Shelton, S., 546
Shimada, J., S569
Shurin, P. A., 506
Siber, G. R., 566
Siegenthaler, W., S581
Sierra, M. F., S406
Silberblatt, F., S360
Silvius, J. R., S50
Simberkoff, M. S., 562
Simmen, H., S581
Simmons, B. P., 665
Smellie, J. M., 461
Smith, A. L., 566
Smith, P. F., S1, S109
Solomons, N. W., 859
Souney, P., 29
Spicehandler, J., 562
Stamm, A. M., 665
Stamm, W. E., 450, 484
Stanbridge, E. J., S219, S227
Standiford, H. C., S585
Stetten, D., Jr., 915
Stevens, C. E., 491
Stevens, D. P., 851
Stoeckel, K., 372
Strickland, G. T., 951
Stuart, R. K., 586
Stuart-Harris, C., 913
Stubenbord, W. T., 1208
Sugden, B., 1048
Sunquist, H., 358
Surgalla, M. J., 351
Tatem, B., S585
Tatlock, H., 147, 157
Tessler, S. S., S546
Thadepalli, H., 1113
Then, R. L., 261, 372
Thomas, E. D., 1119
Thompson, S. E. III, S747
Thomson, M. J., 438
Thornsberry, C., S300, S316, S366, S848
Tolkoff-Rubin, N. E., 444, 614
Tomkins, L. S., 1220
Tonkin, R. W., 619
Towner, K. J., 456
Trissl, D., 1154
Truog, K., 593
Tsagarakis, J., S629
Tuazon, C. U., 97
Tully, J. G., S1, S129, S137, S141, S148, S154, S193
Turck, M., S281, 450, 484
Ueda, Y., S569
Ulmer, C., Jr., S396
Van Beers, D., 173
Van Camp, B., 173
van Gestel, M., S527
Variyam, E. P., 830
Waldvogel, F. A., S491
Wallace, R. J., Jr., 315, 326
Warren, K. S., 715, 771, 955
Washington, A. E., S727, S758, S857, S864
Washington, J. A., II, S511
Webber, J. A., S496
Weber, D., 444
Whitcomb, R. F., S129, S148, S154
Wieslander, Å., S43
Wilkinson, R., 444
Williams, J. D., 351
Williams, T. W., Jr., 315
Williamson, D., S129
Williamson, D. L., S137
Wills, P. J., S564
Winston, D. J., S650, S676
Wise, K. S., S210
Wise, R., S564, S581
Wiss, K., 326
Wittman, D. H., S610
Wold, J. S., S536, S555
Wright, N., S564
Wyler, D. J., 785
Yolken, R. H., 35
Yoshida, T., S496
Young, L. S., 608, S489, S650
Yu, V. L., 1236
Zinner, S. H., 294
Zuravleff, J. J., 1236

Subject Index

Acetaldehyde, effect of moxalactam and moxalactam plus ethanol on concentration in blood, S555
Acholeplasma laidlawii
  active diffusion of adsorbed mycoplasmal virus L3 on cell membranes, S105
  antigenic architecture of cell membranes, S73
  comparison of composition and molecular organization with those of mycoplasmal virus L2, S99
  lipid-phase transition of phosphatidylglycerol in membranes, S80
  receptor sites for mycoplasmal viruses, S109
  regulation of lipid composition in membranes by lipid phase structure, S43
Acholeplasma laidlawii B, molecular properties of membrane lipids and ATPase activity, S50
Adenosine triphosphatase, from *A. laidlawii* B membranes, effects of membrane lipid fluidity and phase state on activity, S50
Aerobic gram-negative bacilli, activity of cefotaxime vs. selected β-lactams, S401
Alimentary process, effects of parasitic diseases, 763
Allopurinol, and drug-induced fever, 69
Amebiasis
  host immune response, 1185
  host-pathogen biology, 836
  infection with *E. histolytica*, 1247
  immunity and immunoprophylaxis, 1247
  infection with *E. histolytica*, 1247
  parasite cellular mechanisms, 1185
  pathogenesis of, 1185
  relation to host nutritional status, 843, 896
Aminoglycosides
  pathogenesis of nephrotoxicity, review, S360
  synergy with β-lactams, 237
  synergy with cell wall–active agents, 282
Amoxicillin
  single-dose therapy for urinary tract infections in women, 29
  vs. trimethoprim-sulfamethoxazole, for treatment of acute otitis media, 506
Ampicillin
  more effective than trimethoprim-sulfamethoxazole against *S. pneumoniae* meningitis in rabbits, 311
  plus probenecid, vs. trimethoprim-sulfamethoxazole, for treatment of concomitant *N. gonorrhoeae* and *C. trachomatis* infections in women, 491
  vs. trimethoprim-sulfamethoxazole, for treatment of acute infectious exacerbations of chronic bronchitis, 196, 517
  vs. trimethoprim-sulfamethoxazole, otitis, 506
Anaerobic bacteria
  antibiotic resistance, 1075
  biochemical mechanisms of, 1075
  genetic transfer of, 1075
  treatment of infections due to
    with trimethoprim-sulfamethoxazole, 338
    with moxalactam, S511
Analogues, of trimethoprim, characterization, 372
Anemia, iron-deficiency, in hookworm disease, 824, 830
Antagonism, of parasitic diseases and malnutrition, 746
Antibody, heterophile, in infectious mononucleosis, classic article, 1062
Antibiotics, *See also names of specific drugs*
  drug-induced fever, 69
  for treatment of tree diseases associated with mycoplasma-like organisms, S157, S162, S167
  resistance, of *E. cloacae*, 13
  single-dose therapy for urinary tract infections in women, 29
  susceptibility tests, correlation between results with cefotaxime and clinical bacteriologic response, S316
Anticonvulsant drugs, and drug-induced fever, 69
Antigens
  infectious, in body fluids, detection by enzyme immunoassay, 35
  protein, of *A. laidlawii*, expression on cell surfaces, S73
Antihypertensive drugs, and drug-induced fever, 69
Arthritis
  chronic, due to *C. albicans*, in patients with acute myeloblastic leukemia, 1071
  septic
    due to *Candida* species in patients with cancer, 78
    treatment with cefotaxime, S465, S472
Ascariasis
  host-pathogen biology, 806
  lack of evidence for adverse effects on host nutritional status, 815
  relation to host nutritional status, 815, 896
Ascaris lumbricoides
  life cycle, host response, 806
  nutritional implications of infections, 815
Astrocytes, structure, viral infections, 999
Bacilli, gram-negative, use of synergistic antibiotics in treatment of infection, 294
Bacillus cereus, panophthalmitis, source of the organism and association with heroin abuse, 97
Bacteremia
  due to *S. aureus*, in patients with cancer, 1
  epidemiology, and antibiotic resistance of *E. cloacae*, 13
  treatment with cefotaxime, efficacy and safety, S411
Bacteriuria, risks and need for clinical studies, 434
Bacteroides fragilis, treatment of sc abscesses in mice with moxalactam, clindamycin, cefoxitin, carbenicillin, cephalothin, ampicillin, and cefotaxime, S664
Bacteroides species, susceptibility to moxalactam, S511
Basophils, in vitro evidence for importance in protection from parasitic infections, 698
Blast transformation, of resting lymphocytes by mycoplasmas, S205, S219
Body size, functional significance in malnourished populations, 736
Bronchial secretions, levels of cefotaxime, S392
Bronchitis, chronic
  long-term trimethoprim-sulfamethoxazole prophylaxis, 196, 528
  treatment of acute infectious exacerbations

with trimethoprim-sulfamethoxazole, 196, 528
with trimethoprim-sulfamethoxazole or ampicillin, 196, 517
Burkitt's lymphoma, African, lymphoproliferative disease associated with Epstein-Barr virus, 1048
Bursitis, septic, treatment with cefotaxime, S465
Cancer
caused by retroviruses, 1015
empiric therapy with trimethoprim-sulfamethoxazole plus carbenicillin in neutropenic patients, 586
hepatocellular, as late sequela of persistent hepatitis B viral infection, 1026
in humans, and *S. aureus* bacteremia, 1
nasopharyngeal, association with Epstein-Barr virus, 1048
treatment of concomitant infections with trimethoprim-sulfamethoxazole, 579
Candida albicans
cause of chronic arthritis in patients with acute myeloblastic leukemia, 1071
urinary tract infections, treatment, 1107
Candida species, septic arthritis in patients with cancer, 78
Carbenicillin, combined with trimethoprim-sulfamethoxazole, as empiric therapy for neutropenic cancer patients, 586
Cefoperazone
disk susceptibility testing against Enterobacteriaceae, S516
pharmacokinetics, S585
Cefotaxime
activity against *H. influenzae* and aerobic gram-negative bacilli, comparison with selected β-lactams, S401
activity against *Y. enterocolitica, E. corrodens,* and penicillin-resistant *S. pncumoniae*, S406
adverse reactions
in patients with bacteremia, S411
in perspective, and other cephalosporins, S481
correlation of clinical bacteriologic response with susceptibility test results, S316
disk susceptibility testing against Enterobacteriaceae, S516
and desacetylcefotaxime, synergy, comparative activity, S366, S374
efficacy and safety for treatment of bacteremia, S411
in vitro antimicrobial properties and spectrum, review, S300
levels in body fluids and tissues, review, S346
levels in bronchial secretions, S392
levels in cerebrospinal fluid of rabbits with *E. coli* meningitis, S396
mechanisms of bacterial resistance, S288
metabolism in animals and humans, S325, S333
nephrotoxicity, need for sensitive studies, S360
new cephalosporin, current status, symposium, S281–S488
pharmacokinetics, S585
in patients with normal and reduced renal function, S333, S379
symposium, S281–S488
toxicity, animal studies and clinical reports, S354
for treatment
of bacterial infections of lower respiratory tract, comparison with cefazolin, S421
of gram-negative bacillary meningitis, S453
of peritonitis and other soft-tissue infections, comparison with gentamicin-clindamycin, S439
of serious bone and joint infections, S465, S472
of serious soft-tissue pelvic infections in obstetric-gynecologic patients, comparison with clindamycin-gentamicin, S432
of skin infections, S444
of uncomplicated gonorrhea, comparison with aqueous procaine penicillin G plus probenicid, S448
of urinary tract infections, comparison with cefazolin, S416
Cellulitis
pelvic, posthysterectomy, treatment with cefotaxime, S432
treatment with cefotaxime, S444
Cephalosporins
and cefotaxime, adverse reactions in perspective, S481
and related antibiotics, overview, S281
pathogenesis of nephrotoxicity, need for sensitive studies, S360
Cerebrospinal fluid of rabbits with *E. coli* meningitis, levels of cefotaxime, moxalactam, and cephalothin, S396
Chancroid
confirmed by culture, S848
therapy, S848
Chlamydial infections
epidemiology, S747
treatment in pregnant women and infants, S747
Chlamydia trachomatis
and *N. gonorrhoeae* infections, concomitant in women, trimethoprim-sulfamethoxazole vs. ampicillin-probenicid treatment, 491
in vitro activity of trimethoprim and/or sulfamethoxazole, 500
Chloramphenicol, treatment of pelvic infections, S696
Cholesterol
in *M. mycoides* subspecies *capri* membranes, effects on potassium transport, S59
possible dual role in biological membranes, S93
uptake by mycoplasmas, S85
Cirrhosis, as late sequela of persistent hepatitis B viral infection, 1026
Clindamycin
treatment of anaerobic infections and antimicrobial activity, 113
treatment of pelvic infections, S696
Clindamycin-gentamicin, vs. cefotaxime, for treatment of soft-tissue infections, S432, S439
Coccidioidomycosis, significance of tissue eosinophilia, 656
Coccidioides immitis, tissue eosinophilia during infection, 656
Condyloma acumenatum, treatment, review, S829
Corynebacteria, nondiphtheria, pathogenicity in humans, 1220
Cystic fibrosis, long-term trimethoprim-sulfamethoxazole treatment, 528
Cystitis, in women, single- vs. multiple-dose trimethoprim-sulfamethoxazole treatment, 484
Derrick Edward Award Lecture, S18
Desacetylcefotaxime, activity, synergy with cefotaxime, S366, S374
Desacetylcefotaxime, in cerebrospinal fluid of rabbits with

E. coli meningitis, S396
Descarboxyprothrombin, functional assays for, S546
Dialysis, associated hepatitis in Edinburgh, 1969–1978, 619
Diarrhea, due to enterotoxigenic *E. coli*, treatment with trimethoprim or trimethoprim-sulfamethoxazole, 540
Diarrhea, travelers', prevention with trimethoprim-sulfamethoxazole, 533
Dihydrofolate reductase, inhibition by three analogs of trimethoprim, 372
Dihydrofolate reductase, plasmid-encoded, trimethoprim-resistant, 246
Disulfiram, effect on concentration of ethanol and acetaldehyde in blood, S555
DNA, sprioplasmal, guanine-plus-cytosine content, hybridization percentages, EcoRI restriction enzyme profiles, S129
Drugs, antimicrobial and antineoplastic, effects on phagocytic and microbicidal function of polymorphonuclear leukocytes, 683
Drugs, antiparasitic, adverse metabolic effects, 768
Edward, Derrick Graham *ff.*, pioneer in mycoplasmology, S3
Effector mechanisms, of immune responses in parasitic diseases, 756
Eikenella corrodens, susceptibility to β-lactams and other agents, S406
Electrochemical proton gradient across mycoplasmal membranes, S65
Elimination vs. eradication and control of disease, definition of terms, 913, 966, 984
Emmy Klieneberger-Nobel Award Lecture, S8
Endocarditis
  bacterial, treatment with trimethoprim-sulfamethoxazole, 196, 338
  experimental infective, in rabbits, treatment with antibiotic combinations, 302
Endometritis, treatment with moxalactam, S701
Endomyometritis, post–cesarean section, treatment with cefotaxime vs. clindamycin-gentamicin, S432
Entamoeba histolytica
  immunity against in animals and humans, 1154
  immunology of, 1154
  nutritional implications of infection, 843
  pathogenic activity, host defense, 836
Enteric infections
  treatment of bacterial, protozoal sexually transmitted, S864
  antimicrobial agents against, S864
Enterobacter cloacae, bacteremia, epidemiology, and antibiotic resistance, 13
Enterococci
  in patients treated with moxalactam, S708
  resistance to moxalactam, S700, S708
Enzyme immunoassays, for infectious antigens in body fluids, 35
Eosinophils
  antihelminthic activity in vivo and in vitro, 698
  in peripheral blood and tissues during coccidioidomycosis, 656
Epidemic hemorrhagic fever, etiology, epidemiology, therapy, 992
Epidemic meningococcal disease, immunoepidemiologic model, 159
Epidemiology
  of *E. cloacae*, 13
  of epidemic hemorrhagic fever, 992
  of malaria and impact of disease on human communities, 798
  of malaria in Malaysia, 985
  of trimethoprim resistance, 270
Epididymitis, epidemiology and treatment of, S788
Epstein-Barr virus
  inducer of lymphoproliferation associated with human disease, 1048
  Paul-Bunnell test, classic paper, 1069
Eradication
  global, of smallpox, influence of biological features of the disease, 916
  of diseases, potential candidates, 931, 933, 940, 951, 955, 966, 984
  see also symposium on eradication of infectious diseases, 912–984
  vs. elimination and control of diseases, definition of terms, 913, 966, 984
Erythrocyte, host, effects of *Plasmodium* species, 785
Escherichia coli
  enterotoxigenic, prevention of diarrhea with trimethoprim-sulfamethoxazole, 533
  enterotoxigenic, treatment of diarrhea with trimethoprim or trimethoprim-sulfamethoxazole, 540
  experimental meningitis in rabbits, penetration of cefotaxime, moxalactam, and cephalothin into cerebrospinal fluid, S396
  resistance to trimethoprim alone, 351, 358, 366
  resistance to trimethoprim-sulfamethoxazole, 351
Experimental infections, in animals, opportunity for study of combination therapy, 262
Fatty acids, in *M. mycoides* subspecies *capri* membranes, effects on potassium transport, S59
Fever, drug-induced, and unexplained fever in hospitalized patients, 69
Folate pathway, cyclic configuration resulting in trimethoprim-sulfamethoxazole synergy, 255
Fort Bragg fever, viral studies, 147, 157
Freeze-fracture technique, for study of *M. pneumoniae*-host interactions, S173
Fungi, treatment of infections with trimethoprim-sulfamethoxazole, 338
Gammopathy (IgG1–2) transient monoclonal, and congenital toxoplasmosis, 173
Gardnerella vaginalis, treatment of leukorrhea caused by, S793
Genetics, of trimethoprim resistance, 270
Genital disease, due to *M. pulmonis* in rodents, S18
Genitourinary disease, in humans, role of *U. urealyticum*, S18
Gentamicin-clindamycin, vs. cefotaxime, for treatment of soft-tissue infections, S432, S439
Giardia species
  life cycle, interation with host, 851
  nutritional aspects of infection, 859
Giardiasis
  host-pathogen biology, 851
  relation to host nutritional status, 859, 896
Gonococcal infections
  prevention of ophthalmia, S758

treatment recommendations, S758
Gonorrhea, uncomplicated, treatment with cefotaxime vs. aqueous procaine penicillin G plus probencid, S448
Gram-negative bacilli, causing meningitis, treatment with new cephalosporins, S453
Granulocytopenia, and prophylaxis of infection with trimethoprim or trimethoprim-sulfamethoxazole, 593
Granulomas, hepatic, pathology, etiology, diagnosis, management, 638
Haemophilus influenzae
activity of cefotaxime vs. selected β-lactams, S401
ampicillin-resistant, treatment of otitis media with trimethoprim-sulfamethoxazole, 196, 514
moxalactam treatment of pneumonia due to, S617
treatment with moxalactam in children with meningitis due to, S597
Helminthic infections, impossibility of eradication, cost-effective strategy for control, 955
Helminths
causing human infections, classic article, 727
interaction with phagocytes in vivo and in vitro, 698
Hemorrhagic fever, epidemic, etiology, therapy, 992
Hepatitis B virus, asymptomatic carriage and mechanisms and consequences of persistent human infection, 1026
Hepatitis
dialysis-associated, in Edinburgh, 1969–1978, 619
granulomatous, pathology, etiology, diagnosis, management, 638
Hepatobiliary infections, treatment with moxalactam, S623
Herpes simplex virus
confusion with chancroid infection,
genital infections caused by,
therapy for genital infections,
Heroin abuse, association with *B. cereus* panophthalmitis, 97
High-pressure liquid chromatography, for estimation of cefotaxime pharmacokinetics in patients with reduced renal function, S333
Hookworm disease
host-pathogen biology, 824
relation to nutritional status, 830, 896
Hypothrombinemia, S546
Immune response
in malaria, 785
in parasitic diseases, effector mechanisms, 756
in parasitic diseases, evasion by parasites, 751, 756
specific and nonspecific effects of mycoplasmas, S201
Immune system, role in interaction of parasitic diseases and malnutrition, 746
Immunizations and infectious diseases, advances in the 1970s, 136
Immunosuppression, as reason for use of synergistic antibiotic combinations, 294
Industry, role in development of a product for control of mycoplasma-like plant diseases, S162
Infections
biliary tract, treatment with moxalactam therapy, S688
gynecologic, treatment with moxalactam, S701
intraabdominal, treatment with moxalactam, S670
obstetric, treatment with moxalactam, S701
ophthalmic, treatment with trimethoprim-sulfamethoxazole, 338
pelvic, treatment with moxalactam
after cesarean delivery, S696
with postpartum endometritis and pelvic inflammatory disease, treatment with moxalactam, S701
surgical
treatment with moxalactam, S676
treatment with moxalactam and clindamycin plus aminoglycoside, S683
urinary tract, efficacy of moxalactam in hospitalized patients, S692
Infectious diseases
and immunizations, advances in the 1970s, 136
control, vs. eradication and elimination, definition of terms, 913, 966, 984
eradication, symposium, 912–984
Infertility, human, role of *U. urealyticum*, S18
International Conference on the Eradication of Infectious Diseases
report, 913–984
conclusions and recommendations, 984
Intestines, physiology and function, effects of parasitic diseases, 763
Klebsiella pneumoniae
resistance to trimethoprim-sulfamethoxazole, 351
synergy of cephalothin and gentamicin, variation with method and criteria used for determination, 276
β-Lactam antibiotics
areas of concern for future development, S491, S720
comparison of in vivo and in vitro antibacterial activity, S501
history of development by chemical modifications in relation to moxalactam, S489, S491
mechanisms of bacterial resistance, S288
susceptibility of *Y. enterocolitica*, *E. corrodens*, and *S. pneumoniae*, S406
synergy with aminoglycosides, 237
synergy with β-lactamase inhibitors, 282
β-Lactamases
effect on activity of 25 β-lactam antibiotics, S501
inhibition of, by moxalactam, S522
kinetics of inactivation by moxalactam in vitro, S529
resistance of moxalactam to, in sc abscesses due to *B. fragilis* in mice, S664
results of in vitro tests for induction of, by cefoxitin, cefuroxime, cefamandole, ceftazidime, cephalothin, moxalactam, cefaperazone, and cefotaxime, S527
susceptibility to moxalactam, S529
Leukemia, acute myeloblastic, concomitant with chronic candida arthritis, 1071
Leukorrhea, *G. vaginalis*-associated, S793
Lipids, membrane
of *A. laidlawii*, molecular properties and ATPase activity, S50
of *A. laidlawii*, regulation of composition by lipid phase structure, S43
of *M. capricolum*, physical state, S35
Listeria monocytogenes, infection in renal transplant recipients, 665
Listeriosis, in renal transplant recipients, 665
Lymphocytes, mitogenic activation by mycoplasmas, S205, S219

Lymphoproliferation, induced by Epstein-Barr virus, reflection in human diseases, 1048
Macrophages, anthelminthic activity in vivo and in vitro, 698
Malaria
  discovery of parasite, etiology, classic article, 908
  epidemiology in Malaysia, 985
  host-pathogen biology, 785
  relation to host nutritional status, 798, 896
  treatment with trimethoprim-sulfamethoxazole, 196, 419
Malnutrition
  effects on host-parasite relation
    in amebiasis, 843
    in giardiasis, 859
    in malaria, 798
    in schistosomiasis, 771, 776
Malnutrition
  functional consequences, 736
  lack of evidence for ascariasis as cause, 815
  synergy and antagonism with parasitic diseases, 746
Mast cells, in vitro evidence for importance in protection from parasitic infection, 698
Measles, candidate for global eradication, 933, 966
Membranes
  mycoplasmal, electrochemical proton gradient, S65
  of *M. mycoides* subspecies *capri*, effects of cholesterol and fatty acid content on potassium transport, S59
Meningitis
  bacterial
    treatment with moxalactam in children, S597
    treatment with trimethoprim-sulfamethoxazole, 196, 338
  due to *E. coli*, in rabbits, penetration of cefotaxime, moxalactam, and cephalothin into cerebrospinal fluid, S396
  due to *S. pneumoniae*, in rabbits, superiority of ampicillin to trimethoprim-sulfamethoxazole, 311
  experimental, in rabbits and dogs, treatment with antibiotic combinations, 302
  gram-negative bacillary
    treatment with moxalactam, S606
    treatment with new cephalosporins, S453
  neonatal, treatment with moxalactam, S603
  survey of treatments used, S606
  treatment with moxalactam, S623
  in rabbits, S595
Metabolism, adverse effects of antiparasitic drugs, 768
Metronidazole, treatment of vaginal trichomoniasis, S801
Methyltetrazolethiol, effect on acetaldehyde concentration in blood, S555
Microbicidal activity, of polymorphonuclear leukocytes, effects of antimicrobial and antineoplastic drugs, 683
Microorganisms, phagocytosis, biology and disease, 104
Mitogenicity, of mycoplasmas toward lymphocytes, S205, S219
Models, animal, for cefotaxime toxicity studies, suitability of rats and dogs, S325
Mononucleosis, infectious
  lymphoproliferative disease caused by Epstein-Barr virus, 1048
  presence of heterophile antibodies, classic article, 1062
Moxalactam
  absorption and excretion of, in children treated for septicemia, bronchitis, pneumonia, urinary tract infections, lymphadenitis, or skin and soft tissue infections, S656
adverse reactions, S650
  disulfiram-like reaction when taken with ethanol, S555
  in patients treated for pelvic infections after cesarean delivery, S696
  in patients treated for urinary tract infections, S692
against anaerobic bacterial isolates from clinical specimens, S511
vs. cephalothin, cefoxitin, and cefotaxime
  against isolates from nosocomial infections, S629
  in treatment of serious infections, S629
vs. clindamycin, cefoxitin, chloramphenicol, cefotaxime, carbenicillin, cephalothin, ampicillin, and cefoperazone
  in treatment of sc abscesses due to *B. fragilis* in mice, S654
vs. clindamycin plus an aminoglycoside in treatment of serious surgical infections, S516
disk susceptibility testing against Enterobacteriaceae, S516
effect on acetaldehyde concentrations during ethanol metabolism, S555
effect on blood coagulation and platelet function in volunteers with thromboembolism, S546
epimers of
  influence of probenecid on the pharmacokinetics
  MICs for 23 organisms, S581
levels
  in bile of patients treated for serious biliary tract infections, S564
  in cerebrospinal fluid
    of children with meningitis, S597, S656
    of infants during treatment of meningitis, S603
    of patients with gram-negative bacillary meningitis, S606
    of rabbits with bacterial meningitis, S603
    of rabbits with *E. coli* meningitis, S396
  in serum and infected sites of mice with sc abscesses due to *B. fragilis*, S664
  in serum of patients with normal or impaired renal function, S564
  in serum of women treated for postpartum endometritis and pelvic inflammatory disease, S70
  in serum, bile, and urine of normal volunteers after im, iv, and bolus administration, S569
  in tissue and tissue fluids of normal volunteers and patients with osteoarthritis or who had undergone laparotomies, S610
nephrotoxicity, in rabbits, S536
pharmacokinetics
  in animals as basis for dosage recommendations for treatment of bacillary meningitis of infancy, S603
  in normal volunteers after im, iv, and bolus iv administration, S569
  in serum of neonates and young infants with gram-negative bacillary meningitis, S595
  in serum and tissue fluids of normal volunteers and patients with osteoarthritis or who had undergone laparotomies, S610
relation of chemical structure to antimicrobial function, S496
resistance to, in *Bacteroides* species, gram-positive cocci, enterococci, *M. hominis*, and *P. anaerobius* isolated

from pelvic infections, S701
as single-drug therapy for patients with intraabdominal infections, post-operative wound sepsis, or septicemia, S676
spectrum of activity against gram-positive and gram-negative bacteria in vivo and in vitro, S501
vs. standard antibiotic therapy in clinical trials with hospitalized patients, S639
superinfections
due to *C. albicans*, enterococci, *S. aureus*, or *S. epidermidis* in patients treated for intraabdominal infections, postoperative wound sepsis, or septicemia, S676
in patients treated for respiratory and hepatobiliary infections, meningitis, and septicemia, S623
in patients treated for serious infections, S639
in patients treated for urinary tract infections, S708
with *P. aeruginosa*, *Candida* and enterococci in patients treated for nosocomial infections, S650
symposium, S489–S726
teratogenicity and effect on reproduction in rats, mice, rabbits, and dogs, S536
toxicity, in rodents and rabbits, S536
for treatment
of bacterial infections, S712
of infections in hospitalized patients, S639
of meningitis, septicemia, bronchitis, pneumonia, urinary tract infections, and lymphadenitis or skin and soft-tissue infections in children, S656
of respiratory tract infections, hepatobiliary infections, meningitis, and septicemia in patients in Japan, S623
Mycobacterium, nontuberculous species, in vitro activity of trimethoprim and/or sulfamethoxazole, 326
Mycobacterium tuberculosis, epidemiology and treatment of tuberculosis, 1254
Mycoplasma capricolum
physical state of membrane lipids, S35
role of membrane sterols, S93
Mycoplasma hyorhinis, translocation of Thy-1 antigen during interaction with lymphoblastoid ceils, S210, S219
Mycoplasma mycoides subspecies *capri*, effects of cholesterol and fatty acid content of membranes on potassium transport, S59
Mycoplasma pneumoniae
attachment to respiratory epithelial cells, S179, S185
interactions with host, freeze-fracture study, S173
Mycoplasma pulmonis, pathogenic potential in rodents, S18
Mycoplasma-like organisms
antibiotic treatment of associated tree diseases, S157
role of industry in development of a product for control of associated plant diseases, S162
Mycoplasma virus L2, molecular organization and selective solubilization of lipids and proteins in the envelope, S99
Mycoplasma virus L3, adsorption and active diffusion on *A. laidlawii* cell membranes, S105
Mycoplasma viruses, receptor sites on *A. laidlawii*, S109
Mycoplasmas
attachment to host cell membranes, S185
electrochemical proton gradient across membranes, S65
immunologic interactions with host cells, S201
mitogenic activity toward lymphocytes, S205, S219
possible adverse effects of oxytetracycline therapy for associated plant diseases, S167
role of interactions with lymphocytes in immunopathologic manifestations of diseases, S219
two-dimensional protein patterns, as aid in taxonomy and strain identification, S8
uptake of cholesterol and phospholipids, S85
Mycoplasmology, symposium and abstracts, S1–S277
Myelin-forming cells, structure, viral infections, 999
Neisseria gonorrhoeae
and C. trachomatis infections, concomitant, in women, trimethoprim-sulfamethoxazole vs. ampicillin-probenicid treatment, 491
penicillinase-producing, infections caused by, S758
review, S758
treatment of infection with cefotaxime or aqueous procaine penicillin G plus probencid, S448
Neisseria meningitidis, epidemic disease, immunoepidemiological model, 159
Nephrotoxicity
of cefotaxime, animal studies and clinical reports, S354
of cefotaxime, need for sensitive studies, S360
of cephalosporins and aminoglycosides, review of pathogenesis, S360
of moxalactam, in rabbits, S536
Nerve cells, differentiated, acute and persistent viral infections, 999
Nervous system, unique interaction of cells with viruses, 999
Neurons, structure, viral infections, 999
Neutropenia, as reason for use of synergistic antibiotic combinations, 294
Neutrophils, anthelmintic activity in vitro, 698
Nitrofurantoin
prophylaxis in children with urinary tract infections and vesicoureteral reflux, 467
prophylaxis of urinary tract infections, 450
vs. trimethoprim, for treatment of acute urinary tract infections, 378
Nocardia, effectiveness of trimethoprim-sulfamethoxazole for treatment of infections, 196, 315
Nocardiosis, effectiveness of trimethoprim-sulfamethoxazole therapy, 196, 315
Nosocomial infections, treatment with moxalactam in critically ill patients with renal failure, S650
Nutrition
and parasitic diseases, symposium, 735–908
functional consequences of deprivation, 736
Nutritional requirements, effects of parasitic diseases, 891
Nutritional status
human, relation to amebiasis, 843, 896, 1247
human, relation to ascariasis, 815, 896
human, relation to giardiasis, 859, 896
human, relation to hookworm disease, 824, 830, 896
human, relation to malaria, 798, 896
human, relation to schistosomiasis, 776, 896
Osteomyelitis
acute and chronic, treatment with cefotaxime, S465, S472
polymicrobial, 86
Otitis media
acute, critical analysis of published trials of antibacterial therapy, 506

acute, trimethoprim-sulfamethoxazole vs. ampicillin or amoxicillin treatment, 506
due to ampicillin-resistant *H. influenzae*, efficacy of trimethoprim-sulfamethoxazole treatment, 196, 514
Oxytetracycline
possible adverse effects of therapy for mycoplasmal plant diseases, S167
safety and efficacy against mycoplasma-like plant diseases, S162
treatment of tree diseases associated with mycoplasma-like organisms, S157, S162, S167
Panophthalmitis, *B. cereus*, source of the organism, 97
Parasites, intracellular, and phagocytic cells, biology and pathophysiology, 124
Parasitic diseases
effects on intestinal physiology and function, 763
effects on nutritional requirements, 891
immune responses, effector mechanisms, 756
immune responses, evasion by parasites, 731, 736
relation of sociocultural factors to transmission and persistence, 871
synergy and antagonism with malnutrition, 746
treatment and control, role of technology vs. science, 885
workshop on interactions with nutrition, 735–911
Parasitic diseases and nutrition
policy implications, 883
priorities for research, 896
symposium, 735–908
Paul-Bunnell test
for heterophile antibodies in infectious mononucleosis, classic article, 1062
historical perspective, 1068, 1069
Pediculosis, treatment with trimethoprim-sulfamethoxazole, 419
Pediculosis pubis, treatment, S857
Pelvic inflammatory disease
acute nongonococcal, treatment with cefotaxime, S432
treatment with moxalactam, S701
therapy, S778
Peritonitis, treatment with cefotaxime vs. gentamicin-clindamycin, S439
Phagocytes
and intracellular parasites, biology and pathophysiology, 124
and worms, David and Goliath revisited, 698
by polymorphonuclear leukocytes, effects of antimicrobial and antineoplastic drugs, 683
of microorganisms, biology and disease, 104
Pharmacokinetics
comparison cefotaxime, moxalactam, and ceftazidime, S581
of carbenicillin, cefoperazone, cefoxitin, cephalothin, chloramphenicol, clindamycin, and moxalactam in treatment of abscesses due to *B. fragilis*, S664
of cefotaxime, in patients with normal and reduced renal function, S333, S379
of moxalactam in biliary tract infections, S688
of moxalactam in gynecologic and obstetric infections, S701
of moxalactam in neonates and young infants, S595
of moxalactam in treatment of bacterial meningitis in children, S597
of moxalactam in treatment of serious nosocomial infections, S629
of moxalactam in treatment of sc abscesses in mice, S664
of moxalactam, cefoperazone, and cefotaxime in normal volunteers, S585
of trimethoprim-sulfamethoxazole, 196, 562, 566
Phosphatidylglycerol, lipid-phase transition in *A. laidlawii* membranes, S80
Phospholipase A_2, for study of lipid-phase transition of phosphatidylglycerol in *A. laidlawii* membranes, S80
Phospholipids, uptake by mycoplasmas, S85
Phthirus pubis, treatment of infection, S857
Plant diseases
associated with mycoplasma-like organisms, role of industry in development of a product for control, S162
mycoplasmal, possible adverse effects of oxytetracycline therapy, S167
Plasmodium species
epidemiology of infection in Malaysia, 985
life cycle, effects on erythrocytes, immune response, 785
nutritional implications of infection, 798
Platelet aggregation, study of suppression by 33 B-lactam antibiotics, S546
Pleuropneumonia-like organisms, isolation from normal mice, classic article, S229
Pneumocystis carinii
lack of activity of trimethoprim alone, 393
treatment and prevention of pneumonitis in children with trimethoprim-sulfamethoxazole, 602
treatment of pneumonia in adults with trimethoprim-sulfamethoxazole, 608
Pneumonia
bacterial, moxalactam therapy, S617
due to *P. carinii*, in adults, treatment with trimethoprim-sulfamethoxazole, 608
nonbacterial, following allogeneic marrow transplantation, 1119
trimethoprim-sulfamethoxazole treatment, 196, 528
due to *P. carinii*, in children, treatment and prevention with trimethoprim-sulfamethoxazole, 602
Poliomyelitis, eradication from U.S., potential for global control, 940, 966
Polyacrylamide gel protein analysis, contribution to spiroplasmal taxonomy, S141
Polyparasitism, prevalence in developing countries, biological implications, 880
Polymorphonuclear leukocytes, effects of antimicrobial and antineoplastic drugs on phagocytic and microbicidal function, 683
Potassium, effects of cholesterol and fatty acid content of *M. mycoides* subspecies *capri* membranes on transport, S59
Probenecid
effect on concentration of moxalactam, S569
influence on pharmacokinetics of cefotaxime, moxalactam, and ceftazidime, S581
Prophylaxis
long-term, with trimethoprim-sulfamethoxazole, for recurrent urinary tract infections in women, 438
of childhood urinary tract infection, trimethoprim vs.

trimethoprim-sulfamethoxazole, 461
of infection in granulocytopenic patients, use of trimethoprim or trimethoprim-sulfamethoxazole, 593
of *P. carinii* pneumonitis in children, use of trimethoprim-sulfamethoxazole, 602
of recurrent urinary tract infection, in infected children with vesicoureteral reflux, 467
of recurrent urinary tract infection, with trimethoprim, trimethoprim-sulfamethoxazole, or nitrofurantoin, 450
of travelers' diarrhea, with trimethoprim-sulfamethoxazole, 533
of urinary tract infection in renal transplant recipients, use of trimethoprim-sulfamethoxazole, 614
Prostatitis, failure of prolonged trimethoprim-sulfamethoxazole treatment, 475
Protein patterns, two-dimensional, of mycoplasmas, as aid in taxonomy and strain identification, S8
Proteus mirabilis, resistance to trimethoprim-sulfamethoxazole, 351
Pseudomonas aeruginosa
causing urinary tract infection, lack of correlation between clinical and bacteriologic response to cefotaxime and susceptibility test results, S316
development of resistance to moxalactam during therapy for bacterial pneumonia, S617
hydrolysis of moxalactam by enzymes from, S650
intraabdominal infections, moxalactam therapy, S670
meningitis, treatment with moxalactam, S606
nosocomial infections, treatment with moxalactam, S650
protection against infection in mice by moxalactam, S501
resistance to moxalactam in serious non-urinary tract infections, S650
resistance to moxalactam in therapy for meningitis, 000
susceptibility to moxalactam and treatment, S656, S629
treatment of pneumonia due to, with moxalactam, S617
Pseudomonas maltophilia, bacteremia, other infections, 1236
Renal function
influence on pharmacokinetics of iv trimethoprim-sulfamethoxazole in children and adults, 566
reduced, effect on cefotaxime pharmacokinetics, S333, S379
Resistance, bacterial
not prevented by trimethoprim-rifampin combination, 390
prevention by use of synergistic antibiotic combinations, 282
to cefotaxime, β-lactams, and other agents, S288
to trimethoprim, after use alone, 358, 366
to trimethoprim and the sulfonamides, results of international laboratory surveillance, 351
to trimethoprim, higher in sulfonamide-resistant than in sulfonamide-susceptible *E. coli*, 351
to trimethoprim, in Paris, genetic aspects, epidemiologic implications, 270
to trimethoprim, increase among coliforms in England, 461
to trimethoprim, increase among urinary tract isolates in United Kingdom, 456
to trimethoprim, molecular mechanisms, 246
to trimethoprim, sulfonamides, and combinations, mechanisms, 261
Respiratory tract infection
lower, bacterial, treatment with cefotaxime vs. cefazolin, S421
M. pulmonis in rodents, S18
treatment with moxalactam, S623
Retroviruses, and cancer, 1015
Rifampicin, combined with trimethoprim
failure to interact synergistically or to prevent resistance, 390
for treatment of urinary tract infections, 402
superior to trimethoprim-sulfamethoxazole against chronic upper urinary tract infections, 402
Rodents, as models of genital tract disease, S18
Salmonella heidelberg, possible animal-to-human transmission of infection, 733, 734
Salmonella, resistance to trimethoprim-sulfamethoxazole, 351
Salmonella typhi, chloramphenicol-resistant and -susceptible, treatment of typhoid fever with trimethoprim-sulfamethoxazole, 196, 551
Salmonellosis
minimal infective dose, 1096
review of outbreaks, 1096
Sarcoptes scabiei var. *hominis*, treatment of infection, S857
Scabies, treatment, S857
Schistosoma mansoni, interaction with phagocytes in vivo and in vitro, 698
Schistosomiasis
cost-effective control, 955
effect of malnutrition, 771, 776
eradication from focal areas, control elsewhere, 951
host-pathogen biology, 771
mansoni-haematobium, classic article, 727
relation to host nutritional status, 776, 896
strategy for control of disease, 715
Sepsis
experimental bacterial, in mice and rats, treatment with antibiotic combinations, 302
neonatal, treatment with trimethoprim-sulfamethoxazole, 338
treatment with moxalactam, S623
treatment with trimethoprim-sulfamethoxazole, 196, 338
Serratia marcescens, resistance to trimethoprim-sulfamethoxazole, 351
Sexually transmitted diseases
editorial, S727
epidemiology in children, S883
in abused children, S883
in rape victims, S877
symposium, S727–S890
Shigellosis, oral or iv trimethoprim-sulfamethoxazole treatment, 546
Skin infections, treatment with cefotaxime, S444
Smallpox, biological features facilitating global eradication, 916
Sociocultural factors, consideration in control and prevention of parasitic diseases, 871
Soft-tissue infections, treatment with cefotaxime vs. gentamicin-clindamycin, S432, S439
Spiroplasma 1 DNA, guanine-plus-cytosine content, hybridization percentages, EcoRI restriction enzyme profiles, S129

Spiroplasmal viruses, group 1 characteristics, S115
Spiroplasmas
comparative properties and emerging taxonomic classifications, S122
interactions with hosts, S193
serologic characterization, S137
taxonomic history and methods for rapid identification, S148
taxonomy, contribution of polyacrylamide gel protein analysis, S141
Staphylococcus aureus
bacteremia in patients with cancer, 1
osteomylitis, 86
Streptococcus pneumoniae
meningitis in rabbits, superiority of ampicillin to trimethoprim-sulfamethoxazole, 311
penicillin-resistant and -susceptible, susceptibility to β-lactams and other agents, S406
Sterols, membrane, role in *M. capricolum*, S93
Sulfamethoxazole
alone and with trimethoprim, in vitro activity against *C. trachomatis*, 500
synergy with trimethoprim in folate pathway, 255
Sulfisoxazole
single-dose therapy for urinary tract infections in women, 29
vs. trimethoprim, for urinary tract infections, 388
Sulfonamides
other than sulfamethoxazole, combined with trimethoprim, 411
resistance mechanisms, 261
Superinfection, after moxalactam treatment, S617, S639, S650, S670, S708
Susceptibility tests
cross-resistance of cefoperazone, cefotaxime, and moxalactam, S516
use of spectral class-representative disks, S516
Synergy
antibiotic, in gram-negative bacillary infections, 294
bactericidal, of β-lactams and aminoglycosides, 237
between agants blocking sequential steps of metabolic pathways, 283
infrequent, with trimethoprim-rifampicin combination, 390
of cefotaxime and desacetylcefotaxime, S366, S374
of cell wall–active agents and aminoglycosides, 282
of β-lactams and β-lactamase inhibitors, 282
of parasitic diseases and malnutrition, 746
of trimethoprim and sulfamethoxazole, in folate pathway, 255
of trimethoprim and sulfamethoxazole, results of international laboratory surveillance, 351
problems in determination, need for standardized methods and criteria, 276, 302
Syphilis
recommendations for examination of cerebrospinal fluid, S842
update on treatment, S837
Taxonomy, of spiroplasmas, S122, S148
Tetracycline, treatment
of nongonococcal urethritis, S842
of tree diseases associated with mycoplasma-like organisms, S157, S162, S167
Thy-1 antigen, translocation during interaction of lymphoblastoid cells and *M. hyorhinis*, S210, S219
Toxicity
caused by trimethoprim and sulfamethoxazole, 196, 429
drug-related, attempts at reduction by use of antibiotic combinations, 282
of cefotaxime, animal studies and clinical reports, S354
of cefotaxime, suitability of rat and dog models, S325
of moxalactam, S536
renal, of cephalosporins and aminoglycosides, review of pathogenesis, S360
Toxoplasmosis
congenital, and transient monoclonal IgG1-λ gammopathy, 173
treatment with trimethoprim-sulfamethoxazole, 196, 419
Transplantation, renal
followed by listeriosis, 665
followed by infection, management, 1208
prophylaxis of subsequent urinary tract infection with trimethoprim-sulfamethoxazole, 614
Travelers' diarrhea, prevention with trimethoprim-sulfamethoxazole, 533
Trees, infections associated with mycoplasma-like organisms, antibiotic treatment, S157
Treponema pallidum, update on treatment of infection, S837
Trichomonas vaginalis, treatment of infection, S801
Trimethoprim
alone and with nonsulfonamides, 402
alone and with sulfamethoxazole, in vitro activity against *C. trachomatis*, 500
characterization of three analogues, 372
combined with rifampicin, failure to interact synergistically or to prevent resistance, 390
combined with rifampicin, for treatment of urinary tract infections, 402
combined with sulfonamides other than sulfamethoxazole, 411
increasing resistance among coliforms in England, 461
increasing resistance among urinary tract isolates in United Kingdom, 456
prophylaxis of recurrent urinary tract infections, 450
resistance, in Paris, genetic aspects, epidemiologic implications, 270
resistance, mechanisms, 246, 261
single-agent treatment and prophylaxis of urinary tract infections, 358, 366
synergy with sulfamethoxazole in folate pathway, 255
vs. nitrofurantoin, for treatment of acute urinary tract infections, 378
vs. sulfisoxazole, for treatment of urinary tract infections, 388
vs. trimethoprim-sulfamethoxazole, for prophylaxis of childhood urinary tract infections, 461
vs. trimethoprim-sulfamethoxazole, for prophylaxis of infection in granulocytopenic patients, 593
vs. trimethoprim-sulfamethoxazole, for treatment of enterotoxigenic *E. coli* diarrhea, 540
Trimethoprim-sulfamethoxazole
adverse reactions, 196, 426, 429

assessment of more than 12 years' use, 196
combined with carbenicillin, as empiric therapy for neutropenic cancer patients, 586
effective treatment for nocardiosis, 196, 315
failure of prolonged therapy for prostatitis, 475
international laboratory surveillance of synergy and resistance, 351
in vitro activity against *C. trachomatis*, 500
iv, for treatment of serious gram-negative infections, 332
iv pharmacokinetics and in vitro bactericidal activity, 562
iv pharmacokinetics in children and adults with normal and impaired renal function, 566
less effective than ampicillin against *S. pneumoniae* meningitis in rabbits, 311
long-term prophylaxis of recurrent urinary tract infections in women, 438
oral or iv, for treatment of shigellosis, 546
prevention of travelers' diarrhea, 533
prophylaxis in children with urinary tract infection and vesicoureteral reflux, 467
prophylaxis of recurrent urinary tract infections, 450
prophylaxis of urinary tract infection in renal transplant recipients, 614
resistance mechanisms, 261
single-dose therapy for urinary tract infections in women, 29
single- vs. multiple-dose treatment of urinary tract infections in women, 444, 484
symposium, 185–618
treatment
and prevention of *P. carinii* pneumonitis in children, 602
of chest infections, 528
of chloramphenicol-resistant and -susceptible typhoid fever, 196, 551
of infections in cancer patients, 579
of malaria, 196, 419
of otitis media due to ampicillin-resistant *H. influenzae*, 196, 514
of *P. carinii* pneumonia in adults, 608
of pediculosis, 419
of recurrent urinary tract infections in men, 449
of severe infections, 338
of toxoplasmosis, 196, 419
v. ampicillin, for acute infectious exacerbations of chronic bronchitis, 196, 517
vs. ampicillin or amoxicillin, for acute otitis media, 506
vs. ampicillin-probenecid, for concomitant *N. gonorrhoeae* and *C. trachomatis* infections in women, 491
vs. trimethoprim alone for enterotoxigenic *E. coli* diarrhea, 540
vs. either drug alone, against nontuberculous mycobacteria in vitro, 326
vs. trimethoprim alone, for prophylaxis of childhood urinary tract infections, 461
vs. trimethoprim alone, for prophylaxis of infection in granulocytopenic patients, 593
Tropism, of viruses for distinct types of nerve cells, 999
Tuberculosis
cost-effective control, 1254
drug therapy for, 1254
etiology (classic paper), 1270
BCG vaccination for, 1254
Typhoid fever, chloramphenicol-resistant and -susceptible, trimethoprim-sulfamethoxazole treatment, 196, 551
Ureaplasma urealyticum, role in human genitourinary disease and infertility, S18
Urethritis, nongonococcal, treatment in men and sexual partners, S842
Urinary tract infection
acute, trimethoprim vs. nitrofurantoin treatment, 378
Candida albicans, as source, 1107
complicated, S692
increased resistance of isolates to trimethoprim, in United Kingdom, 456
in children, trimethoprim vs. trimethoprim-sulfamethoxazole in prophylaxis, 461
in women, single-dose antimicrobial therapy, 29
in women, single- vs. multiple-dose trimethoprim-sulfamethoxazole treatment, 444
prophylaxis of recurrence in infected children with vesicoureteral reflux, 467
recurrent, in men, treatment with trimethoprim-sulfamethoxazole, 449
recurrent, in women, long-term prophylaxis with trimethoprim-sulfamethoxazole, 438
recurrent, prophylaxis with trimethoprim, trimethoprim-sulfamethoxazole, or nitrofurantoin, 450
treatment and prophylaxis with trimethoprim alone, 358, 366
treatment with cefotaxime vs. cefazolin, S416
trimethoprim vs. sulfamethoxazole treatment, 388
trimethoprim-rifampicin treatment, 402
trimethoprim-sulfamethoxazole prophylaxis in renal transplant recipients, 614
vaccines, cost-benefit analysis, 978
Vaccines, current issues, 972
Vesicoureteral reflux, in children with urinary tract infection, trimethoprim-sulfamethoxazole or nitrofurantoin for prophylaxis of recurrent infection, 467
Viral infections, acute and persistent, of differentiated nerve cells, 999
Vitamin K, for prevention of hypothrombinemia associated with use of broad-spectrum antibiotics, S546
Worms, and phagocytes, David and Goliath revisited, 698
Yersinia enterocolitica, susceptibility to β-lactams and other agents, S406

Reviews of Infectious Diseases

Volume 4 • *January–February 1982* • *Number 1*

Contents

Review Articles

Bacteremia due to *Staphylococcus aureus* in Patients with Cancer: Report on 45 Cases in Adults and Review of the Literature. DESMOND N. CARNEY, BYRON E. FOSSIECK, JR., RICHARD H. PARKER, and JOHN D. MINNA 1

Enterobacter cloacae: Bacteremia, Epidemiology, and Antibiotic Resistance. JOSEPH F. JOHN, JR., ROBERT J. SHARBAUGH, and EDWARD R. BANNISTER 13

Single-Dose Therapy for Urinary Tract Infections in Women. PAUL SOUNEY and B. FRANK POLK 29

Enzyme Immunoassays for the Detection of Infectious Antigens in Body Fluids: Current Limitations and Future Prospects. ROBERT H. YOLKEN 35

Drug-Induced Fever: Cases Seen in the Evaluation of Unexplained Fever in a General Hospital Population. EDWARD J. YOUNG, VICTOR FAINSTEIN, and DANIEL M. MUSHER 69

Septic Arthritis due to *Candida* Species in Patients with Cancer: Report of Five Cases and Review of the Literature. VICTOR FAINSTEIN, CAROL GILMORE, ROY L. HOPFER, ANDREW MAKSYMIUK, and GERALD P. BODEY 78

Polymicrobial Osteomyelitis: Report of Three Cases and Review of the Literature. MICHAEL E. PICHICHERO and HOLLEY A. FRIESEN 86

Bacillus cereus Panophthalmitis: Source of the Organism. DALIAH SHAMSUDDIN, CARMELITA U. TUAZON, CHARLES LEVY, and JAMES CURTIN 97

Serial Feature

Phagocytosis of Microorganisms. MARCUS A. HORWITZ 104

Intracellular Parasites and Phagocytic Cells: Cell Biology and Pathophysiology. PAUL J. EDELSON 124

Special Article

Infectious Diseases and Immunizations. JOHN L. SEVER 136

Historical Article

Studies on a Virus from a Patient with Fort Bragg Fever (Pretibial Fever). HUGH TATLOCK ... 147

Editorial: Clarification of the Cause of Fort Bragg Fever—January 1982. HUGH TATLOCK 157

Hypothesis

Epidemic Meningococcal Disease: Synthesis of a Hypothetical Immunoepidemiologic Model. J. MCLEOD GRIFFISS 159

Case Study

Congenital Toxoplasmosis Associated with Transient Monoclonal IgG1-λ Gammopathy. BENJAMIN VAN CAMP, PHILIPPINE REYNAERT, and DANIELLE VAN BEERS 173

Notices 179

Statement of Editorial Policy and Instructions to Authors 180

Parenteral Trimethoprim-Sulfamethoxazole and Carbenicillin as Empiric Therapy for Neutropenic Patients with Cancer. HAYDEN G. BRAINE, ROBERT K. STUART, REIN SARAL, and PAUL S. LIETMAN 586

Trimethoprim-Sulfamethoxazole and Trimethoprim Alone for Prophylaxis of Infection in Granulocytopenic Patients. MARC GURWITH, KAREN TRUOG, DANIEL HINTHORN, and CHIEN LIU 593

Trimethoprim-Sulfamethoxazole Therapy for *Pneumocystis carinii* Pneumonitis in Children. WALTER T. HUGHES 602

Trimethoprim-Sulfamethoxazole in the Treatment of Adults with Pneumonia Due to *Pneumocystis carinii*. LOWELL S. YOUNG 608

A Controlled Study of Trimethoprim-Sulfamethoxazole Prophylaxis of Urinary Tract Infection in Renal Transplant Recipients. NINA E. TOLKOFF-RUBIN, A. BENEDICT COSIMI, PAUL S. RUSSELL, and ROBERT H. RUBIN 614

Volume 4 • *March-April 1982* • *Number 2*

Contents

Summary of the Symposium. EDWARD H. KASS, MAXWELL FINLAND, AND RICHARD PLATT 185

Overview. Trimethoprim-Sulfamethoxazole: An Assessment of More Than 12 Years of Use. ADRIAN J. SALTER 196

Session I: Synergy and Combinations

Bactericidal Synergism Between β-Lactams and Aminoglycosides: Mechanism and Possible Therapeutic Implications. BERNARD D. DAVIS 237

Molecular Mechanisms of Resistance to Trimethoprim. JAMES J. BURCHALL, LYNN P. ELWELL, and MARY E. FLING 246

Synergism in the Folate Pathway. R. J. HARVEY 255

Mechanisms of Resistance to Trimethoprim, the Sulfonamides, and Trimethoprim-Sulfamethoxazole. RUDOLF L. THEN 261

Genetic Aspects and Epidemiologic Functions of Resistance to Trimethoprim. J. F. ACAR and F. W. GOLDSTEIN 270

Problems in Determination of Antibiotic Synergism in Vitro. CARL W. NORDEN 276

Antibiotic Synergism and Antimicrobial Combinations in Clinical Infections. GEORGE M. ELIOPOULOS and ROBERT C. MOELLERING, JR. 282

Synergistic Combinations of Antibiotics in Gram-Negative Bacillary Infections. JEAN KLASTERSKY and STEPHEN H. ZINNER 294

Antibiotic Combinations in Experimental Infections in Animals. JOEL D. ERNST and MERLE A. SANDE 302

Trimethoprim-Sulfamethoxazole Versus Ampicillin in the Treatment of Experimental Meningitis Due to *Streptococcus pneumoniae*. David T. Durack, G. Ralph Corey, and John R. Perfect 311

Use of Trimethoprim-Sulfamethoxazole for Treatment of Infections due to Nocardia. Richard J. Wallace, Jr., Edward J. Septimus, Temple W. Williams, Jr., Richard H. Conklin, Terry K. Satterwhite, Margaret B. Bushby, and Donna C. Hollowell 315

In Vitro Activity of Trimethoprim and Sulfamethoxazole Against the Nontuberculous Mycobacteria. Richard J. Wallace, Jr., Karen Wiss, Margaret B. Bushby, and Donna C. Hollowell 326

Clinical Evaluation of Intravenous Trimethoprim-Sulfamethoxazole for Serious Infections. Uwe Schmidt, Purnendu Sen, Rajendra Kapila, and Donald B. Louria 332

Trimethoprim-Sulfamethoxazole in Treatment of Severe Infections. Adrian J. Salter 338

Session II: Trimethoprim

Laboratory Surveillance of Synergy Between and Resistance to Trimethoprim and Sulfonamides. Thomas F. O'Brien, Jacques F. Acar, G. Altmann, Billie O. Blackburn, Lee Chao, Andre-Louis Courtieu, Denis A. Evans, Manuel Guzman, Marion Holmes, M. R. Jacobs, Ralph L. Kent, Richard A. Norton, H. J. Koornhof, Antone A. Medeiros, A. William Pasculle, Michael J. Surgalla, and J. D. Williams 351

Trimethoprim Alone in the Treatment of Urinary Tract Infections: Eight Years of Experience in Finland. Antero Kasanen and Hannu Sundquist 358

Trimethoprim Alone for Treatment of Urinary Tract Infection. Harold C. Neu 366

New Analogs of Trimethoprim. Rudolf L. Then, Erika Böhni, Peter Angehrn, Helene Plozza-Nottebrock, and Klaus Stoeckel 372

Trimethoprim Once Daily vs. Nitrofurantoin in Treatment of Acute Urinary Tract Infections in Young Women, with Special Reference to Periurethral, Vaginal, and Fecal Flora. Abdollah Iravani, George A. Richard, and Herman Baer 378

Trimethoprim and Sulfisoxazole in the Treatment of Urinary Tract Infections with Special Reference to Antibody-Coated Bacteria and Fecal Flora. Abdollah Iravani, George A. Richard, and Hermann Baer 388

Session III: Combinations of Trimethoprim with Drugs Other Than Sulfonamides

Interactions of Rifampin and Trimethoprim in Vitro. Salvador Alvarez, Alfred DeMaria, Jr., Ranjana Kulkarni, Jerome O. Klein, and William R. McCabe 390

Use of Trimethoprim Alone or in Combination with Drugs Other Than Sulfonamides. William Brumfitt and Jeremy M. T. Hamilton-Miller 402

Combination of Trimethoprim with Sulfonamides Other than Sulfamethoxazole. L. S. Bernstein 411

Trimethoprim-Sulfamethoxazole in the Treatment of Malaria, Toxoplasmosis, and Pediculosis. David B. A. Hutchinson and Jennifer A. Farquhar 419

Session IV: Adverse Effects of Trimethoprim-Sulfamethoxazole

Adverse Reactions to Trimethoprim-Sulfamethoxazole in Hospitalized Patients. Hershel Jick 426

Adverse Reactions to Trimethoprim-Sulfamethoxazole. David H. Lawson and Brian J. Paice 429

Session V: Genitourinary Tract Infections

Editorial: How Important is Bacteriuria? EDWARD H. KASS 434

Long-Term Antimicrobial Prophylaxis for Recurrent Urinary Tract Infection in Women. GODFREY K. M. HARDING, ALLAN R. RONALD, LINDSAY E. NICOLLE, MARGARET J. THOMSON, and GLORIA J. GRAY 438

Single-Dose Therapy with Trimethoprim-Sulfamethoxazole for Urinary Tract Infection in Women. NINA E. TOLKOFF-RUBIN, DAVID WEBER, LESLIE S. T. FANG, MARY KELLY, ROBERT WILKINSON, and ROBERT H. RUBIN 444

Trimethoprim-Sulfamethoxazole Treatment of Men with Recurrent Urinary Tract Infections: A Double-Blind Study Utilizing the Antibody-Coated Bacteria Technique. RICHARD GLECKMAN, MONIQUE CROWLEY, and GEORGE A. NATSIOS 449

Urinary Prophylaxis with Trimethoprim and Trimethoprim-Sulfamethoxazole: Efficacy, Influence on the Natural History of Recurrent Bacteriuria, and Cost Control. WALTER E. STAMM, GEORGE W. COUNTS, MARY MCKEVITT, MARVIN TURCK, and KING K. HOLMES 450

Resistance to Trimethoprim Among Urinary Tract Isolates in the United Kingdom. KEVIN J. TOWNER 456

Trimethoprim-Sulfamethoxazole and Trimethoprim Alone in the Prophylaxis of Childhood Urinary Tract Infection. JEAN M. SMELLIE, R. N. GRÜNEBERG, I. C. S. NORMAND, and HELEN M. BANTOCK 461

Antimicrobial Prophylaxis in Children with Urinary Tract Infection and Vesicoureteral Reflux. NANCY H. HOLLAND, MELODY KAZEE, DENISE DUFF, and J. WILLIAM MCROBERTS 467

Prostatitis: Review of Pharmacokinetics and Therapy. EDWIN M. MEARES, JR 475

Treatment of Cystitis in Women with a Single Dose of Trimethoprim-Sulfamethoxazole. GEORGE W. COUNTS, WALTER E. STAMM, MARY MCKEVITT, KATE RUNNING, KING K. HOLMES, and MARVIN TURCK 484

Treatment of Concomitant *Neisseria gonorrhoeae* and *Chlamydia trachomatis* Infections in Women: Comparison of Trimethoprim-Sulfamethoxazole with Ampicillin-Probenecid. ROBERT C. BRUNHAM, CHO-CHOU KUO, CLAIRE E. STEVENS, and KING K. HOLMES 491

Activity of Trimethoprim-Sulfamethoxazole Against *Chlamydia trachomatis* in Vitro. MARGARET R. HAMMERSCHLAG 500

Session VI: Respiratory Infections

Antibacterial Therapy for Acute Otitis Media: A Critical Analysis. COLIN MARCHANT and PAUL A. SHURIN 506

Trimethoprim-Sulfamethoxazole in the Treatment of Otitis Media Caused by Ampicillin-Resistant Strains of *Haemophilus influenzae*. RICHARD H. SCHWARTZ, WILLIAM J. RODRIGUEZ, WAHEED N. KHAN, RONALD MANN, RONALD G. BARSANTI, and SYDNEY ROSS 514

Comparison of Trimethoprim-Sulfamethoxazole with Ampicillin in Acute Infectious Exacerbations of Chronic Bronchitis: A Double-Blind Crossover Study. SANFORD CHODOSH, BERTRAM EICHEL, CHARLES ELLIS, and TULLIO C. MEDICI 517

The Use of Trimethoprim-Sulfamethoxazole in the Treatment of Chest Infections. DAVID T. D. HUGHES and NICHOLAS J. RUSSELL 528

Session VII: Gastrointestinal Infections

Prevention of Travelers' Diarrhea with Trimethoprim-Sulfamethoxazole. HERBERT L. DU-

PONT, DOLORES G. EVANS, NANCY RIOS, FRANCISCO J. CABADA, DOYLE J. EVANS, JR., and MARGARET W. DUPONT 533

Treatment of Experimentally Induced Enterotoxigenic *Escherichia coli* Diarrhea with Trimethoprim, Trimethoprim-Sulfamethoxazole, or Placebo. ROBERT E. BLACK, MYRON M. LEVINE, MARY LOU CLEMENTS, LUIS CISNEROS, and VELMA DAYA 540

Oral or Intravenous Trimethoprim-Sulfamethoxazole Therapy for Shigellosis. JOHN D. NELSON, HELEN KUSMIESZ, and SHARON SHELTON 546

Response of Typhoid Fever Caused by Chloramphenicol-Susceptible and Chloramphenicol-Resistant Strains of *Salmonella typhi* to Treatment with Trimethoprim-Sulfamethoxazole. THOMAS BUTLER, LARRY RUMANS, and KEITH ARNOLD 551

Session VIII: Parenteral Use of Trimethoprim-Sulfamethoxazole

Intravenous Pharmacokinetics and in Vitro Bactericidal Activity of Trimethoprim-Sulfamethoxazole. JONATHAN SPICEHANDLER, ALAN A. POLLOCK, MICHAEL S. SIMBERKOFF, and JAMES J. RAHAL, JR. 562

Pharmacokinetics of Intravenous Trimethoprim-Sulfamethoxazole in Children and Adults with Normal and Impaired Renal Function. GEORGE R. SIBER, CATHERINE C. GORHAM, JON F. ERICSON, and ARNOLD L. SMITH 566

Session IX: The Immunocompromised Host

Use of Trimethoprim-Sulfamethoxazole for Treatment of Infections in Patients with Cancer. GERALD P. BODEY, WILLIAM E. GROSE, and MICHAEL J. KEATING 579

Volume 4 • *May–June 1982* • *Number 3*

Contents

Review Articles

Dialysis-Associated Hepatitis in Edinburgh; 1969–1978. B. P. MARMION, C. J. BURRELL, R. W. TONKIN, and J. DICKSON 619

Granulomatous Hepatitis. PAUL T. HARRINGTON, JOSE J. GUTIERREZ, CARLOS H. RAMIREZ-RONDA, RAFAEL QUINONES-SOTO, RAMON H. BERMUDEZ, and JAMES CHAFFEY 638

Tissue Eosinophilia in Human Coccidioidomycosis. ROGER M. ECHOLS, DARWIN L. PALMER, and GARY W. LONG 656

Listeriosis in Renal Transplant Recipients: Report of an Outbreak and Review of 102 Cases. ALAN M. STAMM, WILLIAM E. DISMUKES, BRYAN P. SIMMONS, C. GLENN COBBS, ANN ELLIOTT, PEGGIE BUDRICH, and JOAN HARMON 665

Serial Features

Effects of Antimicrobial and Antineoplastic Drugs on the Phagocytic and Microbicidal Function of the Polymorphonuclear Leukocyte. LIONEL MANDELL 683

Phagocytes and Worms: David and Goliath Revisited. JERROLD J. ELLNER and ADEL A. F. MAHMOUD 698

Selective Primary Health Care: Strategies for Disease Control in the Developing World. Schistosomiasis. KENNETH S. WARREN 715

Classics in Infectious Diseases

Schistosomiasis Mansoni-Haematobium: A Contribution to Human Helminthology. THEODORE BILHARZ 727

Correspondence

Animal-to-Human Disease Transmission. ROBERT W. LYONS 733

Reply. CHARLES E. CHERUBIN 734

Volume 4 • *May–June 1982* • *Supplement*

Contents

Preface. MICHAEL F. BARILE, SHMUEL RAZIN, PAUL F. SMITH, and JOSEPH G. TULLY S1

Derrick Graham ff. Edward: A Pioneer in Mycoplasmology. E. A. FREUNDT S3

The Protein Fingerprints of Mycoplasmas. The Emmy Klieneberger-Nobel Award Lecture. ALAN W. RODWELL S8

The Pathogenic Potential of Mycoplasmas: *Mycoplasma pulmonis* as a Model. The Derrick Edward Award Lecture. GAIL H. CASSELL S18

Session I: Membrane Organization

Physical State of Membrane Lipids of *Mycoplasma capricolum*. DONALD L. MELCHIOR and SHLOMO ROTTEM S35

Lipid Phase Structure in the Regulation of Lipid Composition in *Acholeplasma laidlawii* Membranes. ÅKE WIESLANDER, ANDERS CHRISTIANSSON, LEIF RILFORS, ALI KHAN, LENNART B.-A. JOHANSSON, and GÖRAN LINDBLOM S43

Molecular Properties of Membrane Lipids and Activity of a Membrane Adenosine Triphosphatase from *Acholeplasma laidlawii*. JOHN R. SILVIUS and RONALD N. MCELHANEY S50

Recent Developments in the Study of Potassium Transport in *Mycoplasma mycoides* Subspecies *capri*. C. LE GRIMELLEC and G. LEBLANC S59

The Electrochemical Potential Across Mycoplasmal Membranes. HANS-GERD SCHIEFER and ULRICH SCHUMMER S65

Summary. JOS A. F. OP DEN KAMP S71

Session II: Properties of Mycoplasmal Membranes

Elucidation of the Antigenic Architecture of the *Acholeplasma laidlawii* Cell Membrane by Immunoabsorption in Combination with Crossed Immunoelectrophoresis. KARL-ERIK JOHANSSON and C. I. CHRISTINA JÄGERSTEN S73

Lipid Phase Transition of Phosphatidylglycerol in *Acholeplasma laidlawii* Membranes Studied with Phospholipase A_2. JOS A. F. OP DEN KAMP S80

Cholesterol and Phospholipid Uptake by Mycoplasmas. SHMUEL RAZIN, HAVA EFRATI, SHIRLEY KUTNER, and SHLOMO ROTTEM S85

Role of Membrane Sterols in *Mycoplasma capricolum*. JEAN S. DAHL, CHARLES E. DAHL, and KONRAD BLOCH S93

Summary. SHLOMO ROTTEM S97

Session III: Recent Developments in the Study of Mycoplasmal Viruses

Molecular Organization and Selective Solubilization of Lipids and Proteins in the Envelope of Mycoplasmal Virus L2. SHLOMO ROTTEM and NOA GREENBERG S99

Active Diffusion of Adsorbed Mycoplasmal Virus L3 on *Acholeplasma laidlawii* Cell Membranes. KLAUS HABERER and JACK MANILOFF S105

Receptor Sites on *Acholeplasma laidlawii* for Mycoplasmal Viruses. ABDUL J. N. AL-SHAMMARI and PAUL F. SMITH S109

Spiroplasmal Viruses: Group I Characteristics. ALAN LISS and ROGER M. COLE. S115

Summary. ROGER M. COLE S120

Session IV: The Spiroplasmas and Their Taxonomic Relationships

Comparative Properties of Spiroplasmas and Emerging Taxonomic Concepts: A Proposal. ROBERT E. DAVIS and ING M. LEE S122

Guanine-Plus-Cytosine Content, Hybridization Percentages, and EcoRI Restriction Enzyme Profiles of Spiroplasmal DNA. J. M. BOVÉ, C. SAILLARD, P. JUNCA, J. R. DEGORCE-DUMAS, B. RICARD, A. NHAMI, R. F. WHITCOMB, D. WILLIAMSON, and J. G. TULLY S129

Characterization of Spiroplasmas by Serology. DAVID L. WILLIAMSON and JOSEPH G. TULLY S137

Polyacrylamide Gel Analysis of Spiroplasmal Proteins and Its Contribution to the Taxonomy of Spiroplasmas. CLAUDE MOUCHES, ANNIE MENARA, JOSEPH G. TULLY and JOSEPH M. BOVÉ S141

Taxonomy and Identification of Spiroplasmas. ROBERT F. WHITCOMB and JOSEPH G. TULLY S148

Summary. JOSEPH G. TULLY, JOSEPH M. BOVÉ, and ROBERT F. WHITCOMB. S154

Session V: Current Aspects in the Control of Plant Mycoplasmal Diseases

Antibiotic Treatment for Control of Tree Diseases Associated with Mycoplasma-like Organisms. RANDOLPH E. MCCOY S157

Editorial: The Role of Industry in the Development of a Product for Control of Mycoplasmal Plant Diseases. VINCENT J. CARROLL S163

Editorial: Possible Adverse Effects of Antibiotic Therapy in Plants. M. J. DANIELS S167

Summary. RANDOLPH E. MCCOY S171

Session VI: Host-Pathogen Interactions

Host-Pathogen Interactions in Experimental *Mycoplasma pneumoniae* Disease Studied by the Freeze-Fracture Technique. JOHNNY L. CARSON and ALBERT M. COLLIER S173

A Review of the Morphological and Biochemical Features of the Attachment Process in Infections with *Mycoplasma pneumoniae*. MICHAEL G. GABRIDGE S179

Attachment of Mycoplasmas to Host Cell Membranes. ITZHAK KAHANE, MENACHEM BANAI, SHMUEL RAZIN, and JÜRGEN FELDNER S185

Interaction of Spiroplasmas with Plant, Arthropod, and Animal Hosts. JOSEPH G. TULLY ... S193

Summary. JOEL B. BASEMAN S200

Session VII: Mycoplasmal Immunity and Immunopathology

Immunologic Interactions Between Host Cells and Mycoplasmas: An Introduction. GERALD W. FERNALD S201

In Vitro Studies on the Mitogenic Activity of Mycoplasmal Species Toward Lymphocytes. YEHUDITH NAOT S205

Translocation of Thy-1 Antigen and a Fluorescent Lipid Probe During Lymphoblastoid Cell Interaction with *Mycoplasma hyorhinis*. KIM S. WISE, F. CHRIS MINION, and HERBERT C. CHEUNG S210

Mycoplasma-Lymphocyte Interactions and Their Possible Role in Immunopathologic Manifestations of Mycoplasmal Disease. ERIC J. STANBRIDGE S219

Summary. ERIC J. STANBRIDGE S227

Classics in Infectious Diseases

The Occurrence in Normal Mice of Pleuropneumonia-like Organisms Capable of Producing Pneumonia. DERRICK G. FF. EDWARD S229

Abstracts S237

Author Index to Papers and Abstracts S278

Volume 4 • *July–August 1982* • *Number 4*

Contents

Participants vi

Introduction to the Workshop. GERALD T. KEUSCH 735

General Concepts

Functional Consequences of Malnutrition. DORIS HOWES CALLOWAY 736

Synergism and Antagonism of Parasitic Diseases and Malnutrition. WILLIAM R. BEISEL 746

Immune Responses in Parasitic Diseases. Part A: General Concepts. GERALD T. KEUSCH 751

Immune Responses in Parasitic Diseases. Part B: Mechanisms. R. K. CHANDRA 756

Intestinal Physiology and Parasitic Diseases. IRWIN H. ROSENBERG and BARBARA B. BOWMAN 763

Adverse Metabolic Effects of Antiparasitic Drugs. MICHAEL KATZ 768

Problems Posed by Specific Parasitic Diseases

Schistosomiasis: Host-Pathogen Biology. KENNETH S. WARREN 771

Schistosomiasis: Nutritional Implications. C. AMECHI AKPOM 776

Discussion: Schistosomiasis and Malnutrition. HEONIR ROCHA 783

Malaria: Host-Pathogen Biology. DAVID J. WYLER 785

Malaria: Nutritional Implications. IAN A. MCGREGOR 798

Discussion: Malaria and Malnutrition. MICHAEL KATZ 805

Ascariasis: Host-Pathogen Biology. ZBIGNIEW S. PAWLOWSKI 806

Ascariasis: Nutritional Implications. Myron G. Schultz 815
Discussion: Ascariasis, Hookworm Disease, and Malnutrition. Vinodini Reddy 820
Discussion: Ascariasis, Hookworm Disease, and Malnutrition. Michael C. Latham 822
Hookworm Disease: Host-Pathogen Biology. Robert H. Gilman 824
Hookworm Disease: Nutritional Implications. Easwaran P. Variyam and John G. Banwell 830
Amebiasis: Host-Pathogen Biology. Bernardo Sepúlveda 836
Amebiasis: Nutritional Implications. Louis S. Diamond 843
Giardiasis: Host-Pathogen Biology. David P. Stevens 851
Giardiasis: Nutritional Implications. Noel W. Solomons 859
Discussion: Amebiasis, Giardiasis, and Malnutrition. Leonardo Mata 870

Conclusions

Sociocultural Factors in the Control and Prevention of Parasitic Diseases. Leonardo Mata 871
Biological Implications of Polyparasitism. Gerald T. Keusch and Panata Migasena 880
Interactions of Parasitic Diseases and Nutrition: Some Policy Implications. James M. Pines .. 883
The Treatment and Control of Parasitic Diseases. Philip Davis Marsden 885
Nutritional Requirements in Parasitic Diseases. Doris Howes Calloway 891
Needed Research on the Interactions of Certain Parasitic Diseases and Nutrition in Humans. Michael C. Latham 896

Summary and Recommendations. Gerald T. Keusch 901

Classics in Infectious Diseases

A Newly Discovered Parasite in the Blood of Patients Suffering from Malaria. Parasitic Etiology of Attacks of Malaria. Charles Louis Alphonse Laveran 908

Volume 4 • *September-October 1982* • *Number 5*

Contents

Report on the International Conference on the Eradication of Infectious Diseases. Can Infectious Diseases Be Eradicated?

Participants 912
Foreword. Sir Charles Stuart-Harris 913
Introduction. DeWitt Stetten, Jr. 915

A Successful Eradication Campaign

The Global Eradication of Smallpox. Frank Fenner 916
How Should We Assess the Importance of an Infection? Discussion 931

Potential Candidates for Eradication

World Eradication of Measles. Alan R. Hinman 933

Eradication of Poliomyelitis in the United States. NEAL NATHANSON 940
Schistosomiasis: Eradication or Control? G. THOMAS STRICKLAND 951
The Present Impossibility of Eradicating the Omnipresent Worm. KENNETH S. WARREN ... 955
Eradication, Elimination, and Control: Which Disease Next? Discussion 966
Vaccine-Related Issues. Discussion 972
Cost-Benefit Analysis. Discussion 978
Conclusions and Recommendations 984

Review Articles

Epidemiology of Malaria in Malaysia. K. M. MAQSUDUR RAHMAN 985
Epidemic Hemorrhagic Fever Revisited. MYRON S. COHEN 992
Persistent Viral Infections: A Collection of Reviews
Introduction. ALICE S. HUANG 998
Acute and Persistent Viral Infections of Differentiated Nerve Cells. M. DUBOIS-DALCQ, B. RENTIER, E. HOOGHE-PETERS, M. V. HASPEL, R. L. KNOBLER, and K. HOLMES 999
Retroviruses and Cancer. HARRIET LATHAM ROBINSON 1015
Persistent Infection of Humans with Hepatitis B Virus: Mechanisms and Consequences. DONALD GANEM 1026
Epstein-Barr Virus: A Human Pathogen Inducing Lymphoproliferation in Vivo and in Vitro. BILL SUGDEN 1048

Classics in Infectious Diseases

The Presence of Heterophile Antibodies in Infectious Mononucleosis. JOHN R. PAUL and W. W. BUNNELL 1062
Excerpts from The History of Infectious Mononucleosis. ALFRED S. EVANS 1068
Editorial. The Paul-Bunnell Test Revisited. CLYDE S. CRUMPACKER II 1069

Correspondence

Chronic Candida Arthritis in Leukemic Patients. MICHAEL P. GLAUSER, JEAN C. GERSTER, and FRANÇOISE DELACRÉTAZ 1071

Erratum (Austrian, Robert. 3(Suppl.):1–17, 1981) 1071

Notice 1072

Volume 4 • *September–October 1982* • *Supplement*

Contents

Participants ..... Svi
Introduction: Cephalosporins and Related Antibiotics: An Overview. MARVIN TURCK S281

Session I: Basic Science

Mechanisms of Bacterial Resistance to Antimicrobial Agents, with Particular Reference to Cefotaxime and Other β-Lactam Compounds. HAROLD C. NEU S288

Cefotaxime: A Review of in Vitro Antimicrobial Properties and Spectrum of Activity. RONALD N. JONES and CLYDE THORNSBERRY S300

Antimicrobial Susceptibility Tests with Cefotaxime and Correlation with Clinical Bacteriologic Response. CLYDE THORNSBERRY, RONALD N. JONES, ARTHUR L. BARRY, and PETER C. FUCHS S316

Metabolism of Cefotaxime in Animals and Humans. JAMES D. COOMBES S325

Clinical Pharmacokinetics of Cefotaxime in Patients with Normal and Reduced Renal Function. JAMES T. DOLUISIO S333

Levels of Cefotaxime in Body Fluids and Tissues: A Review. WILLIAM J. NOVICK, JR. S346

Cefotaxime Toxicity Studies: A Review of Preclinical Studies and Some Clinical Reports. BRUCE I. DOERR, REMI GLOMOT, HEINRICH KIEF, MARTIN KRAMER, and TAKASHI SAKAGUCHI S354

Pathogenesis of Nephrotoxicity of Cephalosporins and Aminoglycosides: A Review of Current Concepts. FRED SILVERBLATT S360

Antimicrobial Activity of Desacetylcefotaxime Alone and in Combination with Cefotaxime: Evidence of Synergy. RONALD N. JONES, ARTHUR L. BARRY, and CLYDE THORNSBERRY S366

Antibacterial Activity of Desacetylcefotaxime Alone and in Combination with Cefotaxime. HAROLD C. NEU S374

The Pharmacokinetics of Cefotaxime and its Metabolites in Subjects with Normal and Impaired Renal Function. ROBERT M. J. INGS, JEAN-PAUL FILLASTRE, MICHEL GODIN, ANNIE LEROY, and GUY HUMBERT S379

Penetration of Cefotaxime into Bronchial Secretions. E. BERGOGNE-BEREZIN, C. MOREL, J. PIERRE, N. MONROCQ, P. DOURNOVO, and Y. BENARD S392

Penetration of Cefotaxime and Moxalactam into Cerebrospinal Fluid of Rabbits with Experimentally Induced *Escherichia coli* Meningitis. CHARLES M. NOLAN and CLYDE ULMER, JR. ... S396

Comparative Activity of Cefotaxime and Selected β-Lactam Antibiotics Against *Haemophilus influenzae* and Aerobic Gram-Negative Bacilli. H. J. DABERNAT and C. DELMAS S401

Comparative Susceptibility of *Yersinia enterocolitica, Eikenella corrodens*, and Penicillin-Resistant and Penicillin-Susceptible *Streptococcus pneumoniae* to β-Lactam and Alternative Antimicrobial Agents. ELLIE J. C. GOLDSTEIN, CHARLES E. CHERUBIN, MICHAEL L. CORRADO, and MARCELINO F. SIERRA S406

Session II: Clinical Studies

Clinical Experience with Cefotaxime in the Treatment of Patients with Bacteremia. BURT R. MEYERS S411

Treatment of Urinary Tract Infections with Cefotaxime: Noncomparative and Prospective Comparative Trials. PAUL O. MADSEN S416

Clinical Trials of Cefotaxime for the Treatment of Bacterial Infections of the Lower Respiratory Tract. ROBERT L. PERKINS S421

Clinical Experience with Cefotaxime in Obstetric and Gynecologic Infections. DAVID L. HEMSELL, F. GARY CUNNINGHAM, CHARLES M. NOLAN, and TIMOTHY T. MILLER S432

Clinical Comparison of Cefotaxime with Gentamicin Plus Clindamycin in the Treatment of Peritonitis and Other Soft-Tissue Infections. H. HARLAN STONE, EVELYN S. MORRIS, CAROL E. GEHEBER, LAURA D. KOLB, and WILLIAM E. DUNLOP S439

Cefotaxime in the Treatment of Infections of the Skin and Skin Structure. RICHARD V. MCCLOSKEY, RONALD GOREN, DEBORAH BISSETT, JUDITH BENTLEY, and VICTORIA TUTLANE S444

Treatment of Uncomplicated Gonorrhea with Cefotaxime. H. HUNTER HANDSFIELD S448

Treatment of Gram-Negative Bacillary Meningitis: Role of the New Cephalosporin Antibiotics. CHARLES E. CHERUBIN, MICHAEL L. CORRADO, S. RAMACHANDRAN NAIR, MYLES E. GOMBERT, SHELDON LANDESMAN, and GUY HUMBERT S453

Clinical Experience with Cefotaxime in the Treatment of Serious Bone and Joint Infections. JACK L. LEFROCK and BERNICE B. CARR S465

Cefotaxime Therapy for Patients with Osteomyelitis and Septic Arthritis. JOHN T. MADER, JACK L. LEFROCK, KENNETH C. HYAMS, ABDOLGADHER MOLAVI, and JAMES A. REINARZ S472

Session III: Safety and Tolerance

Cefotaxime and Cephalosporins: Adverse Reactions in Perspective. CRAIG R. SMITH S481

Volume 4 • *November–December 1982* • *Number 6*

Contents

Review Articles

Antibiotic Resistance to Anaerobic Bacteria: Molecular Biology and Clinical Aspects. ROGER E. BAWDON, LAWRENCE R. CRANE, and SUNIL PALCHAUDHURI 1075

A Review of Human Salmonellosis: I. Infective Dose. MARTIN J. BLASER and LEE S. NEWMAN 1096

Urinary Tract Infections Due to *Candida albicans*. JOHN F. FISHER, WILLIAM H. CHEW, SMITH SHADOMY, RICHARD J. DUMA, C. GLEN MAYHALL, and WILLIAM C. HOUSE 1107

Nonbacterial Pneumonia After Allogeneic Marrow Transplantation: A Review of Ten Year's Experience. JOEL D. MEYERS, NANCY FLOURNOY, and E. DONNALL THOMAS 1119

Clindamycin: A Review of Fifteen Years of Experience. VINOD K. DHAWAN and HARAGOPAL THADEPALLI 1133

Immunology of *Entamoeba histolytica* in Human and Animal Hosts. DOROTHEA TRISSL ... 1154

A Review of the Parasite Cellular Mechanisms Involved in the Pathogenesis of Amebiasis. JONATHAN I. RAVDIN and RICHARD L. GUERRANT 1185

Infection Following Renal Transplantation: A Changing Pattern. HENRY MASUR, JHOONG S. CHEIGH, and WILLIAM T. STUBENBORD 1208

Infections Caused by Nondiphtheria Corynebacteria. BENJAMIN A. LIPSKY, ALLEN C. GOLDBERGER, LUCY S. TOMPKINS, and JAMES J. PLORDE 1220

Infections Caused by *Pseudomonas maltophilia* with Emphasis on Bacteremia: Case Reports and a Review of the Literature. JEFFREY J. ZURAVLEFF and VICTOR L. YU 1236

Amebiasis: Host-Pathogen Biology. BERNARDO SEPÚLVEDA 1247

Serial Features

Selective Primary Health Care: Strategies for Control of Disease in the Developing World. II. Tuberculosis. THOMAS M. DANIEL 1254

Classics in Infectious Diseases

Excerpts from *The Natural History of Pliny* 1266

The Etiology of Tuberculosis. ROBERT KOCH 1270

Notice 1275

Index to Volume 4 1277

Volume 4 • *November–December 1982* • *Supplement*

Contents

Participants ..... Svi

Introduction

Preface. LOWELL S. YOUNG and ROBERT C. MOELLERING, JR. S489

Editorial. The Future of β-Lactam Antibiotics. FRANCIS A. WALDVOGEL S491

Session I: Chemistry and in Vitro Activity of Moxalactam and Mechanisms of Resistance

Moxalactam: The First of a New Class of β-Lactam Antibiotics. J. ALAN WEBBER and TADASHI YOSHIDA S496

In Vitro and in Vivo Antibacterial Activity of Moxalactam, an Oxa-β-Lactam Antibiotic. SACHIKO GOTO S501

In Vitro Activity of Moxalactam Against Anaerobic Bacteria. MARY J. R. GILCHRIST and JOHN A. WASHINGTON II S511

Differences Among Moxalactam, Cefoperazone, and Cefotaxime in Activity Against Multiple-Antibiotic–Resistant Gram-Negative Bacteria. DAVID A. PRESTON S516

Susceptibility of Moxalactam to β-Lactamase. MARK H. RICHMOND S522

Absence of β-Lactamase–Inducing Effect of Moxalactam. R. P. MOUTON, M. VAN GESTEL, and G. P. A. BONGAERTS S527

Moxalactam: An Oxa-β-Lactam Antibiotic that Inactivates β-Lactamases. ROGER LABIA ... S529

Session II: Toxicity and Pharmacokinetics of Moxalactam

An Evaluation of the Toxicity of Moxalactam in Laboratory Animals. YOSHIO HARADA, FUMIHIKO KOBAYASHI, YOSHIHIRO MURAOKA, YASUHIKO HASEGAWA, JOHN S. WOLD, and DOUGLAS M. MORTON S536

Effects of Moxalactam on Blood Coagulation and Platelet Function. NILS U. BANG, SALLY S. TESSLER, ROBERT O. HEIDENREICH, CAROLE A. MARKS, and LAWRENCE E. MATTLER S546

Ethanol-Moxalactam Interactions in Vivo. MILDRED K. BUENING and JOHN S. WOLD S555

Activity, Stability, and Pharmacology of the Epimers of Moxalactam. R. WISE, N. WRIGHT, and P. J. WILLS S564

Moxalactam—Absorption, Excretion, Distribution, and Metabolism. JINGORO SHIMADA and YASUSHI UEDA S569

Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and Ceftazidime. RUEDI LÜTHY, JÜRG BLASER, ANTONIO BONETTI, HANSPETER SIMMEN, RICHARD WISE, and WALTER SIEGENTHALER S581

Comparative Pharmacokinetics of Moxalactam, Cefoperazone, and Cefotaxime in Normal Volunteers. HAROLD C. STANDIFORD, GEORGE L. DRUSANO, WILLIAM B. MCNAMEE, BEVERLY TATEM, PATRICIA A. RYAN, and STEVEN C. SCHIMPFF S585

Pharmacokinetics of Moxalactam in Neonates and Young Infants. GEORGE H. MCCRACKEN, JR. and URS B. SCHAAD S595

Pharmacology and Cerebrospinal Fluid Penetration of Moxalactam in Children and Dosage Recommendations. SHELDON L. KAPLAN, EDWARD O. MASON, JR., SALLY J. KVERNLAND, ELAINE L. CALAWAY, and RALPH D. FEIGIN S597

The Pharmacologic Basis for Moxalactam Therapy for Gram-Negative Enteric Bacillary Meningitis of Infancy. GEORGE H. MCCRACKEN, JR., and URS B. SCHAAD S603

Moxalactam Therapy for Gram-Negative Bacillary Meningitis. JAMES J. RAHAL, JR. S606

Distribution of Moxalactam in Serum, Bone, Tissue Fluid, and Peritoneal Fluid. DIETMAR H. WITTMANN and HANS-H. SCHASSAN S610

Session III: Use of Moxalactam in Medical Patients

Moxalactam Therapy for Bacterial Pneumonia. CARL A. PERLINO S617

Clinical Evaluation of Moxalactam in the Treatment of Respiratory Tract Infections, Hepatobiliary Infections, and Septicemia. AKIRA SAITO S623

Moxalactam in Serious Infections: Clinical, Bacteriologic, and Pharmacokinetic Studies. HELEN GIAMARELLOU, JOHN TSAGARAKIS, and GEORGE K. DAIKOS S629

Moxalactam Therapy vs. Standard Antimicrobial Therapy for Selected Serious Infections. MICHAEL J. OBLINGER, JOHN T. BOWERS, MERLE A. SANDE, and GERALD L. MANDELL S639

Moxalactam for Treatment of Nosocomial Infections. DREW J. WINSTON, TERRANCE O. KURTZ, LOWELL S. YOUNG, and RONALD W. BUSUTTIL S650

Absorption, Excretion, and Clinical Efficacy of Moxalactam in Pediatric Patients. RYOCHI FUJII S656

Session IV: Use of Moxalactam in Surgical Patients

Efficacy of Moxalactam in an Animal Model of Subcutaneous Abscesses: Penetration into Infected Sites and in Vivo Activity Against *Bacteroides fragilis*. JOHN G. BARTLETT, KEITH A. JOINER, M. DEZFULIAN, and G. J. R. MARIEN S664

Treatment of Intraabdominal Infection with Moxalactam. TIMOTHY F. MURPHY and MICHAEL BARZA S670

Moxalactam in the Treatment of Intraabdominal Sepsis and Other Surgical Infections. RONALD W. BUSUTTIL, MARIE A. MCGRATTAN, and DREW J. WINSTON S676

Comparison of Moxalactam with the Combination of Clindamycin and an Aminoglycoside in the Treatment of Common Surgical Infections. WILLIAM M. RAMBO, VICTOR E. DEL BENE, LINDA G. BURKEY, CYNTHIA D. COLLINS, and DIANE K. RICHMOND S683

Pharmacokinetics and Clinical Efficacy of Moxalactam in Biliary Tract Infections. O. MUELLER, K. FABRICIUS, E. KRUEGER, and U. RUECKERT S688

Clinical Studies of Moxalactam in Complicated Urinary Tract Infections. JOICHI KUMAZAWA S692

Moxalactam for Treatment of Pelvic Infections After Cesarean Delivery. F. GARY CUNNINGHAM, RONALD S. GIBBS, and DAVID L. HEMSELL S696

Moxalactam Therapy for Obstetric and Gynecologic Infections. STANLEY A. GALL, W. ALLEN ADDISON, and GALE B. HILL S701

Enterococcal Infections in Patients Treated with Moxalactam. ROBERT C. MOELLERING, JR. S708

Session V: Moxalactam in Perspective

Moxalactam: Clinical Summary of Efficacy and Safety. ROBERT B. KAMMER S712

A New Generation of β-Lactam Antibiotics: Anticipating Future Developments and Needs. GEORGE GEE JACKSON S720

Volume 4 *November–December 1982* *Supplement*

Contents

Editorial. Treatment of Sexually Transmitted Diseases: New Additions to An Old Tradition. A. EUGENE WASHINGTON, GERALD L. MANDELL, and PAUL J. WIESNER S727

Sexually Transmitted Diseases: Treatment Guidelines, 1982. CENTERS FOR DISEASE CONTROL . S729

Epidemiology and Treatment of Chlamydial Infections in Pregnant Women and Infants. SUMNER E. THOMPSON III and ROBIN H. DRETLER S747

Update on Treatment Recommendations for Gonococcal Infections. A. EUGENE WASHINGTON S758

Nongonococcal Urethritis: Treatment of Men and Their Sexual Partners. HAROLD W. JAFFE. S772

Pelvic Inflammatory Disease: Considerations Related to Therapy. JAMES T. GOODRICH S778

Epidemiology and Treatment of Epididymitis. D. PETER DROTMAN S788

Gardnerella vaginalis-Associated Leukorrhea: The Disease and Its Treatment. JOSEPH G. LOSSICK S793

Treatment of *Trichomonas vaginalis* Infections. JOSEPH G. LOSSICK S801

Therapy for Symptomatic Genital Herpes Simplex Infection: A Review. MARY E. GUINAN .. S819

Therapy for Condyloma Acuminatum: A Review. STEPHEN MARGOLIS S829

Undate on Recommendations for the Treatment of Syphilis. STUART T. BROWN S837

Examination of Cerebrospinal Fluid in Patients with Syphilis. HAROLD W. JAFFE and SHERWIN A. KABINS S842

Chancroid Therapy: A Review of Cases Confirmed by Culture. STEPHEN J. KRAUS, HARVEY W. KAUFMAN, WILLIAM L. ALBRITTON, CLYDE THORNSBERRY, and JAMES W. BIDDLE S848

Treatment of Scabies and Pediculosis Pubis. WAYNE L. GREAVES, DENNIS D. JURANEK, and A. EUGENE WASHINGTON S857

Treatment of Sexually Transmitted Bacterial and Protozoal Enteric Infections. A. EUGENE WASHINGTON, MYRON G. SCHULTZ, MITCHELL L. COHEN, DENNIS D. JURANEK, and ROBERT L. OWEN S864

Diagnosis and Treatment of Sexually Transmitted Diseases in Rape Victims. CHERYL A. BLACKMORE, ROBERT A. KEEGAN, and WILLARD CATES, JR. S877

Sexually Abused Children and Sexually Transmitted Diseases. DORINE G. KRAMER and JANINE JASON S883